View Filing Data

Print Document View Excel Document

Document and Entity Information Document - shares	9 Months Ended
Document and Entity Information Document - shares	Sep. 30, 2016	Dec. 29, 2016
Entity Information [Line Items]
Entity Registrant Name	ALEXION PHARMACEUTICALS INC
Entity Central Index Key	0000899866
Current Fiscal Year End Date	--12-31
Entity Filer Category	Large Accelerated Filer
Document Type	10-Q
Document Period End Date	Sep. 30, 2016
Document Fiscal Year Focus	2016
Document Fiscal Period Focus	Q3
Amendment Flag	false
Entity Common Stock, Shares Outstanding		223,930,700

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2016	Dec. 31, 2015
Assets
Cash and cash equivalents	$ 761,989	$ 1,010,111
Marketable securities	550,882	374,904
Trade accounts receivable, net	676,837	532,832
Inventories	363,058	289,874
Prepaid expenses and other current assets	241,768	208,993
Total current assets	2,594,534	2,416,714
Property, plant and equipment, net	931,060	697,025
Intangible assets, net	4,467,726	4,707,914
Goodwill	5,037,444	5,047,885
Other assets	262,698	228,343
Total assets	13,293,462	13,097,881
Liabilities and Stockholders' Equity
Accounts payable	44,849	57,360
Accrued expenses	485,234	403,348
Deferred revenue	63,402	20,504
Current portion of long-term debt	322,942	166,365
Current portion of contingent consideration	81,848	55,804
Other current liabilities	36,066	6,234
Total current liabilities	1,034,341	709,615
Long-term debt, less current portion	2,929,384	3,254,536
Facility lease obligation	224,442	151,307
Contingent consideration	126,056	121,424
Deferred tax liabilities	343,794	528,990
Other liabilities	131,342	73,393
Total liabilities	4,789,359	4,839,265
Commitments and contingencies (Note 17)
Stockholders' Equity:
Common stock, $0.0001 par value; 290,000 shares authorized; 231,627 and 230,498 shares issued at September 30, 2016 and December 31, 2015, respectively	23	23
Additional paid-in capital	7,906,523	7,726,560
Treasury stock, at cost, 7,715 and 4,851 shares at September 30, 2016 and December 31, 2015, respectively	(1,110,635)	(710,663)
Accumulated other comprehensive loss	(16,617)	62,301
Retained earnings	1,724,809	1,180,395
Total stockholders' equity	8,504,103	8,258,616
Total liabilities and stockholders' equity	$ 13,293,462	$ 13,097,881

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares shares in Thousands	Sep. 30, 2016	Dec. 31, 2015
Statement of Financial Position [Abstract]
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	290,000	290,000
Common stock, shares issued	231,627	230,498
Treasury Stock, Shares	7,715	4,851

Condensed Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Net product sales	$ 798,524	$ 665,791	$ 2,251,495	$ 1,902,107
Other revenue	582	846	1,765	1,073
Total revenues	799,106	666,637	2,253,260	1,903,180
Cost of sales	71,095	54,057	190,708	175,463
Operating expenses:
Research and development	195,687	165,664	551,288	518,437
Selling, general and administrative	230,128	212,520	694,491	621,019
Amortization of purchased intangible assets	82,036	36,608	242,185	36,608
Change in fair value of contingent consideration	40,290	29,684	30,676	45,707
Acquisition-related costs	0	6,075	2,313	35,852
Restructuring expenses	564	7,461	1,741	30,737
Total operating expenses	548,705	458,012	1,522,694	1,288,360
Operating income	179,306	154,568	539,858	439,357
Other income and expense:
Investment income	4,626	1,967	8,049	7,077
Interest expense	(24,807)	(19,971)	(72,490)	(24,593)
Foreign currency (loss) gain	(1,011)	2,795	(3,740)	1,755
Income before income taxes	158,114	139,359	471,677	423,596
Income tax provision	63,776	323,116	165,113	345,815
Net income (loss)	$ 94,338	$ (183,757)	$ 306,564	$ 77,781
Earnings (loss) per common share
Basic	$ 0.42	$ (0.81)	$ 1.37	$ 0.37
Diluted	$ 0.42	$ (0.81)	$ 1.35	$ 0.37
Shares used in computing earnings per common share
Basic	224,180	226,228	224,454	209,373
Diluted	226,088	226,228	226,560	211,808

Condensed Consolidated Statements of Comprehensive Income Statement - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Net income (loss)	$ 94,338	$ (183,757)	$ 306,564	$ 77,781
Other comprehensive income (loss), net of tax:
Foreign currency translation	488	(1,847)	2,609	(6,065)
Unrealized (losses) gains on marketable securities	(1,910)	135	1,553	389
Unrealized gains on pension obligation	15	8,932	1,225	1,487
Unrealized (losses) gains on hedging activities, net of tax of $(8,694), $(8,011), $(46,057) and $2,998, respectively	(15,904)	(15,308)	(84,305)	1,832
Other comprehensive (loss) income, net of tax	(17,311)	(8,088)	(78,918)	(2,357)
Comprehensive income (loss)	$ 77,027	$ (191,845)	$ 227,646	$ 75,424

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References + Details

Condensed Consolidated Statements of Comprehensive Income (Parenthetical) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Unrealized (losses) gains on hedging activities, net of tax	$ (8,694)	$ (8,011)	$ (46,057)	$ 2,998

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
Cash flows from operating activities:
Net income (loss)	$ 306,564	$ 77,781
Adjustments to reconcile net income to net cash flows from operating activities:
Depreciation and amortization	295,259	72,863
Change in fair value of contingent consideration	30,676	45,707
Share-based compensation expense	151,209	160,853
Deferred taxes	95,771	385,915
Change in excess tax benefit from stock options	0	76,291
Unrealized Gain (Loss) on Derivatives and Commodity Contracts	10,666	769
Other	(921)	(1,837)
Changes in operating assets and liabilities
Accounts receivable	(129,875)	(90,952)
Inventories	(72,190)	(7,368)
Prepaid expenses and other assets	(119,897)	(80,015)
Accounts payable, accrued expenses and other liabilities	92,775	(147,108)
Deferred revenue	43,267	(8,557)
Net cash provided by operating activities	703,304	484,342
Cash flows from investing activities:
Purchases of available-for-sale securities	(655,974)	(372,537)
Proceeds from maturity or sale of available-for-sale securities	485,382	1,092,968
Purchases of trading securities	(6,173)	(12,249)
Proceeds from sale of trading securities	2,337	8,287
Purchases of property, plant and equipment	(225,995)	(206,224)
Payment for acquisition of business, net of cash acquired	0	(3,939,307)
Other	(1,135)	5,479
Net cash used in investing activities	(401,558)	(3,423,583)
Cash flows from financing activities:
Debt issuance costs	0	(45,492)
Proceeds from revolving credit facility	0	200,000
Proceeds from term loan	0	3,500,000
Payments on revolving credit facility	0	(200,000)
Payments on term loan	(175,000)	(57,500)
Equity issuance costs for shares issued in connection with acquisition of business	0	(4,053)
Change in excess tax benefit from stock options	0	(76,291)
Repurchase of common stock	(399,972)	(175,383)
Net proceeds from issuance of common stock under share-based compensation arrangements	27,760	50,824
Payments of contingent consideration	0	(50,000)
Proceeds from development related grants	0	26,000
Other	(5,325)	(1,718)
Net cash (used in) provided by financing activities	(552,537)	3,166,387
Effect of exchange rate changes on cash	2,669	(7,864)
Net change in cash and cash equivalents	(248,122)	219,282
Cash and cash equivalents at beginning of period	1,010,111	943,999
Cash and cash equivalents at end of period	761,989	1,163,281
Supplemental cash flow disclosures from investing and financing activities:
Common stock issued in acquisition of business	0	4,917,810
Capitalization of construction costs related to facility lease obligations	84,838	40,185
Accrued expenses for purchases of property, plant and equipment	$ 22,686	$ 25,165

Business	9 Months Ended
Business	Sep. 30, 2016
Business [Abstract]
Business	Business Alexion Pharmaceuticals, Inc. (Alexion, the Company, we, our or us) is a biopharmaceutical company focused on serving patients with devastating and ultra-rare disorders through the innovation, development and commercialization of life-transforming therapeutic products. In our complement franchise, Soliris® (eculizumab) is the first and only therapeutic approved for patients with either paroxysmal nocturnal hemoglobinuria (PNH), a life-threatening and ultra-rare genetic blood disorder, or atypical hemolytic uremic syndrome (aHUS), a life-threatening and ultra-rare genetic disease. PNH and aHUS are two disorders resulting from chronic uncontrolled activation of the complement component of the immune system. In our metabolic franchise, we commercialize Strensiq® (asfotase alfa) for the treatment of patients with hypophosphatasia (HPP) and Kanuma® (sebelipase alfa) for the treatment of patients with lysosomal acid lipase deficiency (LAL-D). HPP is a genetic ultra-rare disease characterized by defective bone mineralization that can lead to deformity of bones and other skeletal abnormalities. LAL-D is a serious, life threatening ultra-rare disease in which genetic mutations result in decreased activity of the LAL enzyme leading to marked accumulation of lipids in vital organs, blood vessels and other tissues. We are also evaluating additional potential indications for eculizumab in other severe and devastating diseases in which uncontrolled complement activation is the underlying mechanism, and we are progressing in various stages of development with additional product candidates as potential treatments for patients with severe and life-threatening rare disorders.

Basis of Presentation and Principles Of Consolidation	9 Months Ended
Basis of Presentation and Principles Of Consolidation	Sep. 30, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation and Principles of Consolidation	Basis of Presentation and Principles of Consolidation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States for complete financial statements. These accounting principles were applied on a basis consistent with those of the consolidated financial statements contained in the Company's Annual Report on Form 10-K for the year ended December 31, 2015. In our opinion, the accompanying unaudited consolidated financial statements include all adjustments, consisting of normal recurring accruals, necessary for a fair presentation of our financial statements for interim periods in accordance with accounting principles generally accepted in the United States. The condensed consolidated balance sheet data as of December 31, 2015 was derived from audited financial statements but does not include all disclosures required by accounting principles generally accepted in the United States. These interim financial statements should be read in conjunction with the audited financial statements for the year ended December 31, 2015 included in our Annual Report on Form 10-K. The results of operations for the three and nine months ended September 30, 2016 are not necessarily indicative of the results to be expected for the full year. The financial statements of our subsidiaries with functional currencies other than the U.S. dollar are translated into U.S. dollars using period-end exchange rates for assets and liabilities, historical exchange rates for stockholders' equity and weighted average exchange rates for operating results. Translation gains and losses are included in accumulated other comprehensive income (loss), net of tax, in stockholders' equity. Foreign currency transaction gains and losses are included in the results of operations in other income and expense. The accompanying unaudited condensed consolidated financial statements include the accounts of Alexion Pharmaceuticals, Inc. and its subsidiaries. All intercompany balances and transactions have been eliminated in consolidation. Our significant accounting policies are described in Note 1 of the Notes to the Consolidated Financial Statements included in our Annual Report on Form 10-K for the year ended December 31, 2015. New Accounting Pronouncements In May 2014, the Financial Accounting Standards Board (FASB) issued a comprehensive new standard which amends revenue recognition principles and provides a single set of criteria for revenue recognition among all industries. The new standard provides a five step framework whereby revenue is recognized when promised goods or services are transferred to a customer at an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The standard also requires enhanced disclosures pertaining to revenue recognition in both interim and annual periods. The standard is effective for interim and annual periods beginning after December 15, 2017 and allows for adoption using a full retrospective method, or a modified retrospective method. Entities may elect to early adopt the standard for annual periods beginning after December 15, 2016. We are currently assessing the method of adoption and the expected impact the new standard has on our financial position and results of operations. In April 2015, the FASB issued a new standard simplifying the presentation of debt issuance costs. The new standard aligns the treatment of debt issuance costs with debt discounts and premiums and requires debt issuance costs be presented as a direct deduction from the carrying amount of the related debt. We adopted the provisions of this standard in the first quarter 2016 and reclassified $8,635 of deferred financing costs from other current assets to the current portion of long term debt and $26,714 from other non current assets to long-term debt, less current portion in our consolidated balance sheets as of December 31, 2015. In April 2015, the FASB issued a new standard clarifying the accounting for a customer's fees paid in a cloud computing arrangement. Under this standard, if a cloud computing arrangement includes a software license, the customer would account for the software license consistent with other software licenses. If a cloud computing arrangement does not include a software license, the customer would account for the arrangement as a service contract. We adopted the provisions of this standard in the first quarter 2016. The adoption did not have a material effect on our financial condition or results of operations. In February 2016, the FASB issued a new standard requiring that the rights and obligations arising from leases be recognized on the balance sheet by recording a right-of-use asset and corresponding lease liability. The new standard also requires qualitative and quantitative disclosures to understand the amount, timing, and uncertainty of cash flows arising from leases, as well as significant management estimates utilized. The standard is effective for interim and annual periods beginning after December 15, 2018 and requires a modified retrospective adoption. We are currently assessing the impact of this standard on our financial condition and results of operations. In March 2016, the FASB issued a new standard intended to simplify certain aspects of the accounting for employee share-based payments. We elected to early adopt this standard during the third quarter of 2016. One aspect of the standard requires an entity to recognize all excess tax benefits and deficiencies associated with stock-based compensation as a reduction or increase to tax expense in the income statement. Previously, such amounts were recognized in additional paid-in capital. This aspect of the new standard was adopted prospectively, and accordingly we recorded tax benefits of $2,249 and $7,366, respectively, within income tax expense for the three and nine months ended September 30, 2016. The amendments require recognition of excess tax benefits regardless of whether the benefit reduces taxes payable in the current period. As a result, $237,850 associated with previously unrecognized excess tax benefits was recorded as a deferred tax asset and an increase in retained earnings as of the beginning of 2016. Furthermore, the amendment requires that excess tax benefits be classified as an operating activity in the statement of cash flows instead of a financing activity. We elected to adopt this provision of the standard prospectively and thus, prior periods have not been adjusted. We have also elected to continue to estimate the impact of forfeitures when determining the amount of compensation cost to be recognized each period rather than account for forfeitures as they occur.

Acquisitions

9 Months Ended

Sep. 30, 2016

Business Combinations [Abstract]

Business Combination Disclosure [Text Block]

Acquisitions

On May 6, 2015, we announced that we entered into a definitive agreement to acquire Synageva BioPharma Corp. (Synageva), a publicly-held clinical-stage biotechnology company based in Lexington, Massachusetts for per share consideration of $115 in cash and 0.6581 shares of Alexion stock. At this date, the announced purchase consideration was estimated at approximately $8,400,000, net of Synageva cash, based on the closing price of Alexion stock on May 5, 2015 of $168.55.

On June 22, 2015, we completed the acquisition of Synageva, in a transaction accounted for under the acquisition method of accounting for business combinations. Under the acquisition method of accounting, the assets acquired and liabilities assumed from Synageva were recorded as of the acquisition date at their respective fair values. Synageva's results of operations are included in the consolidated financial statements from the date of acquisition. The acquisition furthered our objective to develop and commercialize life-transforming therapies to an increasing number of patients with devastating and rare diseases. Synageva's lead product candidate was Kanuma, an enzyme replacement therapy for patients suffering with LAL-D, a life-threatening, ultra-rare disease for which there were no approved treatments at the closing of the business combination. The U.S. Food and Drug Administration (FDA) and European Commission approved Kanuma in 2015.

We acquired all of the outstanding shares of common stock of Synageva for $4,565,524 in cash and 26,125 shares of common stock. At closing of the business combination on June 22, 2015, the purchase consideration was approximately $8,860,000, net of Synageva cash, based on Alexion's closing share price on the date of acquisition of $188.24. We financed the cash consideration with existing cash and proceeds from our new credit facility described further in Note 6.

The aggregate consideration to acquire Synageva consisted of:



Stock consideration	$	4,917,810
Cash consideration	4,565,524
Total purchase price	$	9,483,334

The following table summarizes the estimated fair values of assets acquired and liabilities assumed:



Cash	$	626,217
Inventory	23,880
In-process research and development (IPR&D)	4,236,000
Deferred tax liabilities, net	(159,991		)
Other assets and liabilities	(26,143		)
Net assets acquired	4,699,963
Goodwill	4,783,371
Total purchase price	$	9,483,334

The fair value of the assets acquired and liabilities assumed were initially based upon preliminary calculations, and our estimates and assumptions were subject to change as we obtained additional information for our estimates during the measurement period (up to one year from the acquisition date). During the nine months ended September 30, 2016, we recorded fair value adjustments of $10,441 primarily due to tax related items.

We acquired $23,880 of Kanuma inventory. The estimated fair value of work-in-process and finished goods inventory was determined utilizing the comparative sales method, based on the expected selling price of the inventory, adjusted for incremental costs to complete the manufacturing process and for direct selling efforts, as well as for a reasonable profit allowance. The estimated fair value of raw material inventory was valued at replacement cost, which is equal to the value a market participant would pay to acquire the inventory.

Intangible assets associated with IPR&D projects primarily relate to Kanuma. The estimated fair value of IPR&D assets of $4,236,000 was determined using the multi-period excess earnings method, a variation of the income approach. The multi-period excess earnings method estimates the value of an intangible asset equal to the present value of the incremental after-tax cash flows attributable to that intangible asset. The fair value using the multi-period excess earnings method was dependent on an estimated weighted average cost of capital for Synageva of 10%, which represents a rate of return that a market participant would expect for these assets.

The excess of purchase price over the fair value amounts of the assets acquired and liabilities assumed represents the goodwill amount resulting from the acquisition. The goodwill, which is not tax-deductible, has been recorded as a noncurrent asset and is not amortized, but is subject to an annual review for impairment. The goodwill represents future economic benefits arising from other assets acquired that could not be individually identified and separately recognized and expected synergies that are specific to our business and not available to market participants, including our unique ability to commercialize therapies for rare diseases, our existing relationships with specialty physicians who can identify patients with LAL-D, a global distribution network to facilitate drug delivery and other benefits that we believe will result from combining the operations of Synageva within our operations.

We recorded a net deferred tax liability of $159,991. This amount was primarily comprised of $602,887 of deferred tax liabilities related to the IPR&D and inventory acquired, offset by $442,896 of deferred tax assets related to net operating loss carryforwards (NOLs), tax credits, and other temporary differences, which we expect to utilize.

For the three and nine months ended September 30, 2015, we recorded $53,721 and $58,356 of pre-tax operating losses, respectively, associated with the continuing operations of Synageva in our condensed consolidated statements of operations.

Pro forma financial information (unaudited)

The following unaudited pro forma information presents the combined results of Alexion and Synageva as if the acquisition of Synageva had been completed on January 1, 2014, with adjustments to give effect to pro forma events that are directly attributable to the acquisition. The unaudited pro forma results do not reflect operating efficiencies or potential cost savings which may result from the consolidation of operations. Accordingly, the unaudited pro forma financial information is not necessarily indicative of the results of operations that would have had we completed the transaction on January 1, 2014.



	Three months ended			Nine months ended
	September 30, 2015			September 30, 2015
Pro forma revenue	$	666,637		$	1,905,388
Pro forma net loss	(177,854		)	(47,565		)
Loss per common share
Basic	$	(0.79	)	$	(0.21	)
Diluted	$	(0.79	)	$	(0.21	)

The unaudited pro forma consolidated results include the following pro forma adjustments related to non-recurring activity:


•	Alexion and Synageva expenses of $33,150 and $127,290, respectively, associated with the accelerated vesting of stock based compensation as a result of the acquisition, were excluded from net income for the nine months ended September 30, 2015.


•	Alexion and Synageva acquisition-related and restructuring costs of $49,367 and $62,071, respectively, were excluded from income for the nine months ended September 30, 2015. Alexion acquisition-related and restructuring costs of $9,223 were excluded from income for the three months ended September 30, 2015.

Acquisition-Related Costs

Acquisition-related costs associated with our business combinations for the three and nine months ended September 30, 2016 and 2015 include the following:



	Three months ended				Nine months ended
	September 30,				September 30,
	2016		2015		2016		2015
Transaction costs ⁽¹⁾	$	—	$	—	$	375	$	26,799
Integration costs	—		6,075		1,938		9,053
	$	—	$	6,075	$	2,313	$	35,852

(1) Transaction costs include investment advisory, legal, and accounting fees

For the three and nine months ended September 30, 2015, the acquisition of Synageva resulted in $3,149 and $13,470 of restructuring related charges, respectively. Synageva restructuring related charges were not material for the three and nine months ended September 30, 2016. See Note 18 for additional details.

- Definition

The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=56956515&loc=d3e1497-128463

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=56956515&loc=d3e1490-128463

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=56956515&loc=d3e1392-128463

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e7008-128479

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=56956515&loc=d3e1486-128463

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=56956791&loc=d3e4845-128472

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=56956515&loc=d3e1500-128463

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=56956515&loc=d3e1524-128463

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e7000-128479

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=56956791&loc=d3e4922-128472

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=56956791&loc=d3e4934-128472

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=56956791&loc=d3e4926-128472

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=56956515&loc=d3e1383-128463

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6996-128479

+ Details

Inventories

9 Months Ended

Sep. 30, 2016

Inventory, Net [Abstract]

Inventories

Inventories are stated at the lower of cost or estimated realizable value. We determine the cost of inventory on a standard cost basis, which approximates average costs.

The components of inventory are as follows:



	September 30,		December 31,
	2016		2015
Raw materials	$	17,005	$	17,924
Work-in-process	192,279		180,324
Finished goods	153,774		91,626
	$	363,058	$	289,874

Intangible Assets and Goodwill

9 Months Ended

Sep. 30, 2016

Goodwill and Intangible Assets Disclosure [Abstract]

Intangible Assets and Goodwill

The following table summarizes the carrying amount of our intangible assets and goodwill, net of accumulated amortization:



		September 30, 2016							December 31, 2015
	Estimated Life (years)	Cost		Accumulated Amortization			Net		Cost		Accumulated Amortization			Net
Licenses	6-8	$	28,507	$	(28,507	)	$	—	$	28,507	$	(28,504	)	$	3
Patents	7	10,517		(10,517		)	—		10,517		(10,517		)	—
Purchased technology	6-16	4,710,495		(358,769		)	4,351,726		4,708,495		(116,584		)	4,591,911
Acquired IPR&D	Indefinite	116,000		—			116,000		116,000		—			116,000
Total		$	4,865,519	$	(397,793	)	$	4,467,726	$	4,863,519	$	(155,605	)	$	4,707,914
Goodwill	Indefinite	$	5,040,345	$	(2,901	)	$	5,037,444	$	5,050,786	$	(2,901	)	$	5,047,885

Amortization expense for the three and nine months ended September 30, 2016 was $82,035 and $242,188, respectively. Amortization expense for the three and nine months ended September 30, 2015 was $36,619 and $36,640, respectively. Total estimated amortization expense for finite-lived intangible assets is $80,035 for the three months ending December 31, 2016, and $320,142 for each of the years ending December 31, 2017 through December 31, 2021.

The following table summarizes the changes in the carrying amount of goodwill:



Balance at December 31, 2015	$	5,047,885
Change in goodwill associated with prior acquisition	(10,441		)
Balance at September 30, 2016	$	5,037,444

Indefinite-lived intangible assets, including IPR&D, are reviewed for impairment annually and whenever events or changes in circumstances indicate that it is more likely than not that the asset is impaired. The value of these assets may become impaired if there are changes since the acquisition date in the underlying assumptions used to estimate expected project sales, development costs and profitability. As of January 4, 2017, we are in the process of completing our annual impairment assessment on our SBC-103 indefinite-lived intangible asset acquired from Synageva. If the results of this assessment indicate that the asset may be impaired, an impairment charge may be recorded during in the fourth quarter of 2016.

- Definition

The entire disclosure for the aggregate amount of goodwill and a description of intangible assets, which may include (a) for amortizable intangible assets (also referred to as finite-lived intangible assets), the carrying amount, the amount of any significant residual value, and the weighted-average amortization period, (b) for intangible assets not subject to amortization (also referred to as indefinite-lived intangible assets), the carrying amount, and (c) the amount of research and development assets acquired and written off in the period, including the line item in the income statement in which the amounts written off are aggregated, if not readily apparent from the income statement. Also discloses (a) for amortizable intangibles assets in total and by major class, the gross carrying amount and accumulated amortization, the total amortization expense for the period, and the estimated aggregate amortization expense for each of the five succeeding fiscal years, (b) for intangible assets not subject to amortization the carrying amount in total and by major class, and (c) for goodwill, in total and for each reportable segment, the changes in the carrying amount of goodwill during the period (including the aggregate amount of goodwill acquired, the aggregate amount of impairment losses recognized, and the amount of goodwill included in the gain (loss) on disposal of a reporting unit). If any part of goodwill has not been allocated to a reportable segment, discloses the unallocated amount and the reasons for not allocating. For each impairment loss recognized related to an intangible asset (excluding goodwill), discloses: (a) a description of the impaired intangible asset and the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method for determining fair value, (c) the caption in the income statement or the statement of activities in which the impairment loss is aggregated, and (d) the segment in which the impaired intangible asset is reported. For each goodwill impairment loss recognized, discloses: (a) a description of the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method of determining the fair value of the associated reporting unit, and (c) if a recognized impairment loss is an estimate not finalized and the reasons why the estimate is not final. May also disclose the nature and amount of any significant adjustments made to a previous estimate of an impairment loss.

+ References + Details

Debt	9 Months Ended
Debt	Sep. 30, 2016
Debt [Abstract]
Debt	Debt In June 2015, Alexion entered into a credit agreement (Credit Agreement) with a syndicate of banks, which provides for a $3,500,000 term loan facility and a $500,000 revolving credit facility maturing in five years. Borrowings under the term loan are payable in quarterly installments equal to 1.25% of the original loan amount, beginning December 31, 2015. Final repayment of the term loan and revolving credit loans are due on June 22, 2020. In addition to borrowings in which prior notice is required, the revolving credit facility includes a sublimit of $100,000 in the form of letters of credit and borrowings on same-day notice, referred to as swingline loans, of up to $25,000. Borrowings can be used for working capital requirements, acquisitions and other general corporate purposes. With the consent of the lenders and the administrative agent, and subject to satisfaction of certain conditions, we may increase the term loan facility and/or the revolving credit facility in an amount that does not cause our consolidated net leverage ratio to exceed the maximum allowable amount. In connection with entering into the Credit Agreement, we paid $45,492 in financing costs which are being amortized as interest expense over the life of the debt. Amortization expense associated with deferred financing costs for the three and nine months ended September 30, 2016 was $2,382 and $7,278, respectively. Amortization expense associated with deferred financing costs for the three and nine months ended September 30, 2015 was $2,513 and $3,864, respectively. We made principal payments of $175,000 during the nine months ended September 30, 2016. As of September 30, 2016, we had $3,281,250 outstanding on the term loan. In December 2016, we made a principle payment of $200,000 on our term loan. As of January 4, 2017, we had $3,081,250 outstanding on the term loan. As of September 30, 2016, we had open letters of credit of $14,632, and our borrowing availability under the revolving facility was $485,368. The fair value of our long term debt, which is measured using Level 2 inputs, approximates book value. Under the Credit Agreement, we are required to deliver to the administrative agent, not later than 50 days after each fiscal quarter, our quarterly financial statements, and within 5 days thereafter, a compliance certificate. In November 2016, we obtained a waiver from the necessary lenders for this requirement and the due date for delivery of the financial statements and compliance certificate was extended to January 18, 2017. The posting of this report on Form 10-Q on our website satisfies the financial statement covenant, and we simultaneously delivered the required compliance certificate, as required by the lenders.

Earnings Per Common Share

9 Months Ended

Sep. 30, 2016

Earnings Per Common Share [Abstract]

Earnings Per Common Share

Basic earnings per common share (EPS) is computed by dividing net income by the weighted-average number of shares of common stock outstanding. For purposes of calculating diluted EPS, the denominator reflects the potential dilution that could occur if stock options, unvested restricted stock units or other contracts to issue common stock were exercised or converted into common stock, using the treasury stock method.

The following table summarizes the calculation of basic and diluted EPS for the three and nine months ended September 30, 2016 and 2015:



	Three months ended					Nine months ended
	September 30,					September 30,
	2016		2015			2016		2015
Net income (loss) used for basic and diluted calculation	$	94,338	$	(183,757	)	$	306,564	$	77,781
Shares used in computing earnings per common share—basic	224,180		226,228			224,454		209,373
Weighted-average effect of dilutive securities:
Stock awards	1,908		—			2,106		2,435
Shares used in computing earnings per common share—diluted	226,088		226,228			226,560		211,808
Earnings (loss) per common share:
Basic	$	0.42	$	(0.81	)	$	1.37	$	0.37
Diluted	$	0.42	$	(0.81	)	$	1.35	$	0.37

We exclude from EPS the weighted-average number of securities whose effect is anti-dilutive. Excluded from the calculation of EPS for the three and nine months ended September 30, 2016 were 4,520 and 4,386 shares of common stock, respectively, because their effect was anti-dilutive. Similarly, we excluded 2,437 shares from the calculation of EPS for the nine months ended September 30, 2015 because their effect was anti-dilutive. For the three months ended September 30, 2015, we reported a net loss; therefore, no outstanding stock awards were included in the computation of diluted net loss per share since such inclusion would have been anti-dilutive.

Marketable Securities

9 Months Ended

Sep. 30, 2016

Investments, Debt and Equity Securities [Abstract]

Marketable securities

Marketable Securities

The amortized cost, gross unrealized holding gains, gross unrealized holding losses and estimated fair value of available-for-sale investments by type of security at September 30, 2016 and December 31, 2015 were as follows:



	September 30, 2016
	Amortized Cost		Gross Unrealized Holding Gains		Gross Unrealized Holding Losses			Estimated Fair Value
Commercial paper	$	238,092	$	—	$	—		$	238,092
Corporate bonds	188,009		32		(237		)	187,804
Municipal bonds	155,421		1		(116		)	155,306
Other government-related obligations:
U.S.	30,503		—		(20		)	30,483
Foreign	133,530		4		(105		)	133,429
Bank certificates of deposit	14,751		—		—			14,751
Total available-for-sale debt securities	$	760,306	$	37	$	(478	)	$	759,865
Equity securities	—		1,775		—			1,775
Total available-for-sale securities	$	760,306	$	1,812	$	(478	)	$	761,640



	December 31, 2015
	Amortized Cost Basis		Gross Unrealized Holding Gains		Gross Unrealized Holding Losses			Aggregate Fair Value
Commercial paper	$	254,396	$	—	$	—		$	254,396
Corporate bonds	133,062		23		(336		)	132,749
Municipal bonds	87,173		1		(63		)	87,111
Other government-related obligations:
U.S.	25,244		—		(94		)	25,150
Foreign	163,403		—		(504		)	162,899
Bank certificates of deposit	27,000		—		—			27,000
Total available-for-sale securities	$	690,278	$	24	$	(997	)	$	689,305

The aggregate fair value of available-for-sale securities in an unrealized loss position as of September 30, 2016 and December 31, 2015 were $348,525 and $293,947, respectively. Investments that have been in a continuous unrealized loss position for more than 12 months were not material. As of September 30, 2016, we believe that the cost basis of our available-for-sale investments is recoverable.

The fair values of available-for-sale securities by classification in the condensed consolidated balance sheet were as follows:



	September 30, 2016		December 31, 2015
Cash and cash equivalents	$	224,179	$	323,218
Marketable securities	537,461		366,087
	$	761,640	$	689,305

The fair values of available-for-sale debt securities at September 30, 2016, by contractual maturity, are summarized as follows:



	September 30, 2016
Due in one year or less	$	508,813
Due after one year through three years	251,052
	$	759,865

As of September 30, 2016 and December 31, 2015, the fair value of our trading securities was $13,421 and $8,817, respectively.

We utilize the specific identification method in computing realized gains and losses. Realized gains and losses on our available-for-sale and trading securities were not material for the three and nine months ended September 30, 2016 and 2015.

- Definition

The entire disclosure for investments in certain debt and equity securities.

+ References + Details

Derivative Instruments and Hedging Activities

9 Months Ended

Sep. 30, 2016

Derivative Instruments and Hedging Activities [Abstract]

Derivative Instruments and Hedging Activities

We operate internationally and, in the normal course of business, are exposed to fluctuations in foreign currency exchange rates. The exposures result from portions of our revenues, as well as the related receivables, and expenses that are denominated in currencies other than the U.S. dollar, primarily the Euro and Japanese Yen. We are also exposed to fluctuations in interest rates on our outstanding term loan debt. We manage these exposures within specified guidelines through the use of derivatives. All of our derivative instruments are utilized for risk management purposes, and we do not use derivatives for speculative trading purposes.

We enter into foreign exchange forward contracts, with durations of up to 60 months, to hedge exposures resulting from portions of our forecasted revenues, including intercompany revenues, that are denominated in currencies other than the U.S. dollar. The purpose of these hedges is to reduce the volatility of exchange rate fluctuations on our operating results and to increase the visibility of the foreign exchange impact on forecasted revenues. These hedges are designated as cash flow hedges upon contract inception. At September 30, 2016, we had open foreign exchange forward contracts with notional amounts totaling $1,902,227 that qualified for hedge accounting.

To achieve a desired mix of floating and fixed interest rates on our term loan, we entered into two interest rate swap agreements in June 2016 that qualified for and are designated as cash flow hedges. The first agreement has a notional amount of $3,281,250 and is effective from June 30, 2016 through December 30, 2016. This agreement hedges the contractual floating interest rate of our term loan. As a result of this agreement, the interest rate for our term loan has been fixed at 0.535%, plus the borrowing spread, until December 30, 2016. The second agreement has a notional amount of $656,250 and is effective December 31, 2016 through December 31, 2019. The second agreement converts the floating rate on a portion of our term loan to a fixed rate of 0.98%, plus a borrowing spread, from December 31, 2016 through December 2019.

The impact on accumulated other comprehensive income (AOCI) and earnings from derivative instruments that qualified as cash flow hedges, for the three and nine months ended September 30, 2016 and 2015 were as follows:



	Three months ended						Nine months ended
	September 30,						September 30,
	2016			2015			2016			2015
Foreign Exchange Contracts:
Gain (loss) recognized in AOCI, net of tax	$	(10,402	)	$	10,206		$	(50,191	)	$	81,794
Gain reclassified from AOCI to net product sales (effective portion), net of tax	$	8,237		$	25,842		$	33,154		$	78,959
Gain (loss) reclassified from AOCI to other income and expense (ineffective portion), net of tax	$	—		$	(328	)	$	—		$	1,003
Interest Rate Contracts:
Gain (loss) recognized in AOCI, net of tax	$	2,517		$	—		$	(1,178	)	$	—
Loss reclassified from AOCI to interest expense, net of tax	$	(218	)	$	—		$	(218	)	$	—

Assuming no change in foreign exchange rates or LIBOR-based interest rates from market rates at September 30, 2016, $22,182 and $(717) of gains (losses) recognized in AOCI will be reclassified to revenue and interest expense, respectively, over the next 12 months.

We enter into foreign exchange forward contracts, with durations of approximately 90 days, designed to limit the balance sheet exposure of monetary assets and liabilities. We enter into these hedges to reduce the impact of fluctuating exchange rates on our operating results. Hedge accounting is not applied to these derivative instruments as gains and losses on these hedge transactions are designed to offset gains and losses on underlying balance sheet exposures. As of September 30, 2016, the notional amount of foreign exchange contracts where hedge accounting is not applied was $569,590.

We recognized a (loss) gain of $(2,528) and $2,676, in other income and expense, for the three months ended September 30, 2016 and 2015, respectively, and $(20,643) and $2,439, for the nine months ended September 30, 2016 and 2015, respectively, associated with the foreign exchange contracts not designated as hedging instruments. These amounts were largely offset by gains or losses in monetary assets and liabilities.

The following tables summarize the fair value of outstanding derivatives at September 30, 2016 and December 31, 2015:



	September 30, 2016
	Asset Derivatives			Liability Derivatives
	Balance Sheet Location	Fair Value		Balance Sheet Location	Fair Value
Derivatives designated as hedging instruments:
Foreign exchange forward contracts	Prepaid expenses and other current assets	$	48,014	Other current liabilities	$	25,831
Foreign exchange forward contracts	Other assets	31,122		Other liabilities	38,392
Interest rate contracts	Prepaid expenses and other current assets	229		Other current liabilities	946
Interest rate contracts	Other assets	—		Other liabilities	797
Derivatives not designated as hedging instruments:
Foreign exchange forward contracts	Prepaid expenses and other current assets	2,306		Other current liabilities	9,113
Total fair value of derivative instruments		$	81,671		$	75,079



	December 31, 2015
	Asset Derivatives			Liability Derivatives
	Balance Sheet Location	Fair Value		Balance Sheet Location	Fair Value
Derivatives designated as hedging instruments:
Foreign exchange forward contracts	Prepaid expenses and other current assets	$	85,058	Other current liabilities	$	1,491
Foreign exchange forward contracts	Other assets	66,309		Other liabilities	4,773
Derivatives not designated as hedging instruments:
Foreign exchange forward contracts	Prepaid expenses and other current assets	6,687		Other current liabilities	4,157
Total fair value of derivative instruments		$	158,054		$	10,421

Although we do not offset derivative assets and liabilities within our condensed consolidated balance sheets, our International Swap and Derivatives Association agreements provide for net settlement of transactions that are due to or from the same counterparty upon early termination of the agreement due to an event of default or other termination event. The following tables summarize the potential effect on our condensed consolidated balance sheets of offsetting our foreign exchange forward contracts and interest rate contracts subject to such provisions:



	September 30, 2016
									Gross Amounts Not Offset in the Condensed Consolidated Balance Sheet
Description	Gross Amounts of Recognized Assets/Liabilities			Gross Amounts Offset in the Condensed Consolidated Balance Sheet		Net Amounts of Assets/Liabilities Presented in the Condensed Consolidated Balance Sheet			Derivative Financial Instruments			Cash Collateral Received (Pledged)		Net Amount
Derivative assets	$	81,671		$	—	$	81,671		$	(49,423	)	$	—	$	32,248
Derivative liabilities	(75,079		)	—		(75,079		)	49,423			—		(25,656		)



	December 31, 2015
									Gross Amounts Not Offset in the Condensed Consolidated Balance Sheet
Description	Gross Amounts of Recognized Assets/Liabilities			Gross Amounts Offset in the Condensed Consolidated Balance Sheet		Net Amounts of Assets/Liabilities Presented in the Condensed Consolidated Balance Sheet			Derivative Financial Instruments			Cash Collateral Received (Pledged)		Net Amount
Derivative assets	$	158,054		$	—	$	158,054		$	(10,421	)	$	—	$	147,633
Derivative liabilities	(10,421		)	—		(10,421		)	10,421			—		—

- Definition

The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 30
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6441202&loc=d3e80720-113993

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4C
-URI http://asc.fasb.org/extlink&oid=56946850&loc=SL5624171-113959

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=56946850&loc=d3e41620-113959

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4B
-URI http://asc.fasb.org/extlink&oid=56946850&loc=SL5624163-113959

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=56946850&loc=SL5579240-113959

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4D
-URI http://asc.fasb.org/extlink&oid=56946850&loc=SL5624177-113959

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=35736893&loc=d3e80784-113994

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=56946850&loc=d3e41641-113959

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 1A
-URI http://asc.fasb.org/extlink&oid=56946850&loc=SL5579245-113959

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4H
-URI http://asc.fasb.org/extlink&oid=56946850&loc=SL5624258-113959

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 30
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=35736893&loc=d3e80748-113994

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4K
-URI http://asc.fasb.org/extlink&oid=56946850&loc=SL5708775-113959

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4J
-URI http://asc.fasb.org/extlink&oid=56946850&loc=SL5708773-113959

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4A
-URI http://asc.fasb.org/extlink&oid=56946850&loc=SL5618551-113959

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 1B
-URI http://asc.fasb.org/extlink&oid=56946850&loc=SL5580258-113959

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4E
-URI http://asc.fasb.org/extlink&oid=56946850&loc=SL5624181-113959

Reference 17: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 25
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6886632&loc=d3e76258-113986

Reference 18: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=56946850&loc=d3e41638-113959

Reference 19: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(n))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

+ Details

Other Investments	9 Months Ended
Other Investments	Sep. 30, 2016
Investments, All Other Investments [Abstract]
Other Investments	Other Investments Other investments include our investment of $37,500 in the preferred stock of Moderna LLC. Our investment is recorded at cost within other assets in our condensed consolidated balance sheets. The carrying value of this investment was not impaired as of September 30, 2016.

Stockholders' Equity	9 Months Ended
Stockholders' Equity	Sep. 30, 2016
Equity [Abstract]
Stockholders' Equity	Stockholders' Equity In November 2012, our Board of Directors authorized a share repurchase program. The repurchase program does not have an expiration date, and we are not obligated to acquire a particular number of shares. The repurchase program may be discontinued at any time at the Company's discretion. In May 2015, our Board of Directors increased the authorization to acquire shares with an aggregate value of up to $1,000,000 for future purchases under the repurchase program, which superseded all prior repurchase programs. Under the program, for the three months ended September 30, 2016 and 2015 we repurchased 536 and 556 shares of our common stock at a cost of $69,321 and $91,820, respectively, and during the nine months ended September 30, 2016 and 2015, we repurchased 2,864 and 1,022 shares of our common stock at a cost of $399,972 and $175,383, respectively. Subsequent to September 30, 2016, we repurchased 250 shares of our common stock under our repurchase program at a cost of $30,695. As of January 4, 2017, there was a total of $325,197 remaining for repurchases under the repurchase program.

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(d),(e))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB TOPIC 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29-31)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB TOPIC 4.C)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Preferred Stock
-URI http://asc.fasb.org/extlink&oid=6521494

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section E

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section C

+ Details

Other Comprehensive Income and Accumulated Other Comprehensive Income

9 Months Ended

Sep. 30, 2016

Accumulated Other Comprehensive Income [Abstract]

Other Comprehensive Income and Accumulated Other Comprehensive Income

The following tables summarize the changes in AOCI, by component, for the nine months ended September 30, 2016 and 2015:



	Defined Benefit Pension Plans			Unrealized Gains (Losses) from Marketable Securities			Unrealized Gains (Losses) from Hedging Activities			Foreign Currency Translation Adjustment			Total Accumulated Other Comprehensive Income (Loss)
Balances, December 31, 2015	$	(9,589	)	$	(785	)	$	92,670		$	(19,995	)	$	62,301
Other comprehensive income before reclassifications	1,003			1,893			(51,369		)	2,609			$	(45,864	)
Amounts reclassified from other comprehensive income	222			(340		)	(32,936		)	—			$	(33,054	)
Net other comprehensive income (loss)	1,225			1,553			(84,305		)	2,609			(78,918		)
Balances, September 30, 2016	$	(8,364	)	$	768		$	8,365		$	(17,386	)	$	(16,617	)



	Defined Benefit Pension Plans			Unrealized Gains (Losses) from Marketable Securities			Unrealized Gains (Losses) from Hedging Activities			Foreign Currency Translation Adjustment			Total Accumulated Other Comprehensive Income (Loss)
Balances, December 31, 2014	$	(16,570	)	$	(234	)	$	87,308		$	(13,719	)	$	56,785
Other comprehensive income before reclassifications	1,394			412			81,794			(6,065		)	77,535
Amounts reclassified from other comprehensive income	93			(23		)	(79,962		)	—			(79,892		)
Net other comprehensive income (loss)	1,487			389			1,832			(6,065		)	(2,357		)
Balances, September 30, 2015	$	(15,083	)	$	155		$	89,140		$	(19,784	)	$	54,428

The table below provides details regarding significant reclassifications from AOCI during the three and nine months ended September 30, 2016 and 2015:



Details about Accumulated Other Comprehensive Income Components	Amount Reclassified From Accumulated Other Comprehensive Income during the three months ended September 30,						Amount Reclassified From Accumulated Other Comprehensive Income during the nine months ended September 30,						Affected Line Item in the Condensed Consolidated Statements of Operations
	2016			2015			2016			2015
Unrealized Gains (Losses) from Hedging Activity
Foreign exchange contracts (effective portion)	$	12,769		$	29,534		$	51,254		$	90,240		Net product sales
Foreign exchange contracts (ineffective portion)	—			(375		)	—			1,146			Foreign currency (loss) gain
Interest rate contracts	(344		)	—			(344		)	—			Interest expense
	12,425			29,159			50,910			91,386
	(4,406		)	(3,645		)	(17,974		)	(11,424		)	Income tax provision
	$	8,019		$	25,514		$	32,936		$	79,962
Unrealized Gains (Losses) from Marketable Securities
Realized gains on sale of securities	$	647		$	—		$	536		$	35		Investment income
	647			—			536			35
	(237		)	—			(196		)	(12		)	Income tax provision
	$	410		$	—		$	340		$	23
Defined Benefit Pension Plans
Amortization of prior service costs and actuarial losses	$	(117	)	$	(313	)	$	(346	)	$	(939	)	(a)
Other	—			821			—			821			(a)
	(117		)	508			(346		)	(118		)
	42			(107		)	124			25			Income tax provision
	$	(75	)	$	401		$	(222	)	$	(93	)

(a) This AOCI component is included in the computation of net periodic pension benefit cost (see Note 15 for additional details).

- Definition

The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=36458714&loc=d3e689-108580

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-URI http://asc.fasb.org/extlink&oid=36458714&loc=SL7669619-108580

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=36458714&loc=d3e640-108580

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 17
-URI http://asc.fasb.org/extlink&oid=36458714&loc=d3e716-108580

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 16
-URI http://asc.fasb.org/extlink&oid=36458714&loc=d3e709-108580

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=36458714&loc=d3e637-108580

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 14
-URI http://asc.fasb.org/extlink&oid=36458714&loc=d3e681-108580

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Reclassification Adjustments
-URI http://asc.fasb.org/extlink&oid=6522872

+ Details

Fair Value Measurement

9 Months Ended

Sep. 30, 2016

Fair Value Disclosures [Abstract]

Fair Value Measurement

Authoritative guidance establishes a valuation hierarchy for disclosure of the inputs to the valuation used to measure fair value. This hierarchy prioritizes the inputs into three broad levels as follows. Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities. Level 2 inputs are quoted prices for similar assets and liabilities in active markets or inputs that are observable for the asset or liability, either directly or indirectly through market corroboration, for substantially the full term of the financial instrument. Level 3 inputs are unobservable inputs based on our own assumptions used to measure assets and liabilities at fair value.

The following tables present information about our assets and liabilities that are measured at fair value on a recurring basis as of September 30, 2016 and December 31, 2015, and indicate the fair value hierarchy of the valuation techniques we utilized to determine such fair value.



		Fair Value Measurement at September 30, 2016
Balance Sheet Classification	Type of Instrument	Total		Level 1		Level 2		Level 3
Cash equivalents	Institutional money market funds	$	83,864	$	—	$	83,864	$	—
Cash equivalents	Commercial paper	$	96,765	$	—	$	96,765	$	—
Cash equivalents	Corporate bonds	$	6,003	$	—	$	6,003	$	—
Cash equivalents	Municipal bonds	$	93,659	$	—	$	93,659	$	—
Cash equivalents	Bank certificates of deposit	$	1,750	$	—	$	1,750	$	—
Cash equivalents	Other government-related obligations	$	26,002	$	—	$	26,002	$	—
Marketable securities	Mutual funds	$	13,421	$	13,421	$	—	$	—
Marketable securities	Commercial paper	$	141,327	$	—	$	141,327	$	—
Marketable securities	Corporate bonds	$	181,801	$	—	$	181,801	$	—
Marketable securities	Municipal bonds	$	61,647	$	—	$	61,647	$	—
Marketable securities	Other government-related obligations	$	137,910	$	—	$	137,910	$	—
Marketable securities	Bank certificates of deposit	$	13,001	$	—	$	13,001	$	—
Marketable securities	Equity securities	$	1,775	$	1,775	$	—	$	—
Prepaid expenses and other current assets	Foreign exchange forward contracts	$	50,320	$	—	$	50,320	$	—
Other assets	Foreign exchange forward contracts	$	31,122	$	—	$	31,122	$	—
Other current liabilities	Foreign exchange forward contracts	$	34,944	$	—	$	34,944	$	—
Other liabilities	Foreign exchange forward contracts	$	38,392	$	—	$	38,392	$	—
Prepaid expenses and other current assets	Interest rate contracts	$	229	$	—	$	229	$	—
Other current liabilities	Interest rate contracts	$	946	$	—	$	946	$	—
Other liabilities	Interest rate contracts	$	797	$	—	$	797	$	—
Current portion of contingent consideration	Acquisition-related contingent consideration	$	81,848	$	—	$	—	$	81,848
Contingent consideration	Acquisition-related contingent consideration	$	126,056	$	—	$	—	$	126,056



		Fair Value Measurement at December 31, 2015
Balance Sheet Classification	Type of Instrument	Total		Level 1		Level 2		Level 3
Cash equivalents	Institutional money market funds	$	179,898	$	—	$	179,898	$	—
Cash equivalents	Commercial paper	$	192,418	$	—	$	192,418	$	—
Cash equivalents	Corporate bonds	$	12,250	$	—	$	12,250	$	—
Cash equivalents	Municipal bonds	$	60,001	$	—	$	60,001	$	—
Cash equivalents	Other government-related obligations	$	31,549	$	—	$	31,549	$	—
Cash equivalents	Bank certificates of deposit	$	27,000	$	—	$	27,000	$	—
Marketable securities	Mutual funds	$	8,817	$	8,817	$	—	$	—
Marketable securities	Commercial paper	$	61,978	$	—	$	61,978	$	—
Marketable securities	Corporate bonds	$	120,499	$	—	$	120,499	$	—
Marketable securities	Municipal bonds	$	27,110	$	—	$	27,110	$	—
Marketable securities	Other government-related obligations	$	156,500	$	—	$	156,500	$	—
Prepaid expenses and other current assets	Foreign exchange forward contracts	$	91,745	$	—	$	91,745	$	—
Other assets	Foreign exchange forward contracts	$	66,309	$	—	$	66,309	$	—
Other current liabilities	Foreign exchange forward contracts	$	5,648	$	—	$	5,648	$	—
Other liabilities	Foreign exchange forward contracts	$	4,773	$	—	$	4,773	$	—
Current portion of contingent consideration	Acquisition-related contingent consideration	$	55,804	$	—	$	—	$	55,804
Contingent consideration	Acquisition-related contingent consideration	$	121,424	$	—	$	—	$	121,424

There were no securities transferred between Level 1, 2 and 3 during the nine months ended September 30, 2016.

Valuation Techniques

We classify mutual fund investments and equity securities, which are valued based on quoted market prices in active markets with no valuation adjustment, as Level 1 assets within the fair value hierarchy.

Cash equivalents and marketable securities classified as Level 2 within the valuation hierarchy consist of institutional money market funds, commercial paper, municipal bonds, U.S. and foreign government-related debt, corporate debt securities and certificates of deposit. We estimate the fair values of these marketable securities by taking into consideration valuations obtained from third-party pricing sources. These pricing sources utilize industry standard valuation models, including both income and market-based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate fair value. These inputs include market pricing based on real-time trade data for the same or similar securities, issuer credit spreads, benchmark yields, and other observable inputs. We validate the prices provided by our third-party pricing sources by understanding the models used, obtaining market values from other pricing sources and analyzing pricing data in certain instances.

Our derivative assets and liabilities include foreign exchange and interest rate derivatives that are measured at fair value using observable market inputs such as forward rates, interest rates, our own credit risk as well as an evaluation of our counterparties’ credit risks. Based on these inputs, the derivative assets and liabilities are classified within Level 2 of the valuation hierarchy.

Contingent consideration liabilities related to acquisitions are classified as Level 3 within the valuation hierarchy and are valued based on various estimates, including probability of success, discount rates and amount of time until the conditions of the milestone payments are met.

As of September 30, 2016, there has not been any impact to the fair value of our derivative liabilities due to our own credit risk. Similarly, there has not been any significant adverse impact to our derivative assets based on our evaluation of our counterparties’ credit risks.

Contingent Consideration

In connection with prior acquisitions, we may be required to pay future consideration that is contingent upon the achievement of specified development, regulatory approvals or sales-based milestone events. We determine the fair value of these obligations on the acquisition date using various estimates that are not observable in the market and represent a Level 3 measurement within the fair value hierarchy. The resulting probability-weighted cash flows were discounted using a cost of debt of 5.5% for developmental milestones and a weighted average cost of capital ranging from 10% to 21% for sales-based milestones.

Each reporting period, we adjust the contingent consideration to fair value with changes in fair value recognized in operating earnings. Changes in fair values reflect new information about the probability and timing of meeting the conditions of the milestone payments. In the absence of new information, changes in fair value will only reflect the interest component of contingent consideration related to the passage of time.

Estimated future contingent milestone payments related to prior business combinations range from zero if no milestone events are achieved, to a maximum of $826,000 if all development, regulatory and sales-based milestones are reached. As of September 30, 2016, the fair value of acquisition-related contingent consideration was $207,904. The following table represents a roll-forward of our acquisition-related contingent consideration:



	Nine months ended
	September 30, 2016
Balance at December 31, 2015	$	(177,228	)
Changes in fair value	(30,676		)
Balance at September 30, 2016	$	(207,904	)

In the fourth quarter 2016, the criteria was met for the achievement of a milestone payment associated with our acquisition of Enobia Pharma Corp. In connection with this, $60,000 was paid in December 2016.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

Income Taxes

9 Months Ended

Sep. 30, 2016

Income Tax Disclosure [Abstract]

Income Taxes

The following table provides a comparative summary of our income tax provision and effective tax rate for the three and nine months ended September 30, 2016 and 2015:



	Three months ended						Nine months ended
	September 30,						September 30,
	2016			2015			2016			2015
Provision for income taxes	$	63,776		$	323,116		$	165,113		$	345,815
Effective tax rate	40.3		%	231.9		%	35.0		%	81.6		%

The tax provision for the three and nine months ended September 30, 2016 and 2015 is attributable to the U.S. federal, state and foreign income taxes on our profitable operations. The decrease in the effective tax rate for the three and nine months ended September 30, 2016 as compared to the same period in the prior year is primarily attributable to a one-time tax charge recorded in Q3 2015 of $315,569 associated with integration of the Synageva business, partially offset by the deferred tax cost associated with a distribution of 2016 earnings from our captive foreign partnership. The partnership earnings we distributed were not previously subject to our indefinite reinvestment assertion.

Tax years 2013 and 2014 are currently under review by the Examination Division of the Internal Revenue Service (IRS). As of September 30, 2016, we have not been notified of any significant proposed adjustments by the IRS.

We continue to maintain a valuation allowance against certain deferred tax assets where realization is not certain.

Defined Benefit Plans

9 Months Ended

Sep. 30, 2016

Compensation and Retirement Disclosure [Abstract]

Employee Benefit Plans

Defined Benefit Plans

We maintain defined benefit plans for employees in certain countries outside the United States, including retirement benefit plans required by applicable local law. The plans are valued by independent actuaries using the projected unit credit method. The liabilities correspond to the projected benefit obligations of which the discounted net present value is calculated based on years of employment, expected salary increases, and pension adjustments.

The components of net periodic benefit cost are as follows:



	Three months ended						Nine months ended
	September 30,						September 30,
	2016			2015			2016			2015
Service cost	$	2,113		$	2,380		$	6,211		$	7,241
Interest cost	56			179			172			551
Expected return on plan assets	(167		)	(248		)	(496		)	(756		)
Employee contributions	(448		)	(442		)	(1,203		)	(1,342		)
Amortization	117			313			346			939
Other	—			(821		)	—			(821		)
	$	1,671		$	1,361		$	5,030		$	5,812

Facility Lease Obligations	9 Months Ended
Facility Lease Obligations	Sep. 30, 2016
Leases [Abstract]
Leases	Facility Lease Obligations New Haven Facility Lease Obligation In November 2012 we entered into a lease agreement for office and laboratory space to be constructed in New Haven, Connecticut. The term of the lease commenced in 2015 and will expire in 2030, with a renewal option of ten years. Although we do not legally own the premises, we are deemed to be the owner of the building due to the substantial improvements directly funded by us during the construction period based on applicable accounting guidance for build-to-suit leases. Accordingly, the landlord's costs of constructing the facility during the construction period are required to be capitalized, as a non-cash transaction, offset by a corresponding facility lease obligation in our consolidated balance sheet. Construction of the new facility was completed and the building was placed into service in the first quarter 2016. As of September 30, 2016 and December 31, 2015, our facility lease obligation related to this facility was $135,442 and $132,866, respectively. Lonza Facility Lease Obligation During the third quarter 2015, we entered into a new agreement with Lonza Group AG and its affiliates (Lonza) whereby Lonza will construct a new manufacturing facility dedicated to Alexion at its existing Portsmouth, New Hampshire facility. The agreement requires us to make certain payments during the construction of the new manufacturing facility and annual payments for ten years thereafter. As a result of our contractual right to full capacity of the new manufacturing facility, a portion of the payments under the agreement are considered to be lease payments and a portion as payment for the supply of inventory. Although we will not legally own the premises, we are deemed to be the owner of the manufacturing facility during the construction period based on applicable accounting guidance for build-to-suit leases due to our involvement during the construction period. As of September 30, 2016 and December 31, 2015, we recorded a construction-in-process asset of $100,068 and $19,259 and an offsetting facility lease obligation of $89,668 and $15,229 associated with the manufacturing facility, respectively. Payments to Lonza under the agreement are allocated to the purchases of inventory and the repayment of the facility lease obligation on a relative fair value basis. In 2016, we incurred $49,000 of payments to Lonza under this agreement, of which $6,370 was applied against the outstanding facility lease obligation and $42,630 was recognized as a prepayment of inventory.

Commitments and Contingencies	9 Months Ended
Commitments and Contingencies	Sep. 30, 2016
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies Commitments Manufacturing Agreements We have various manufacturing development agreements to support our clinical and commercial product needs. We rely on Lonza, a third party manufacturer, to produce a portion of commercial and clinical quantities of Soliris and Strensiq. We have various agreements with Lonza, with remaining total non-cancellable future commitments of approximately $1,122,029. If we terminate certain supply agreements with Lonza without cause, we will be required to pay for product scheduled for manufacture under our arrangement. Under an existing arrangement with Lonza, we also pay Lonza a royalty on sales of Soliris manufactured at Alexion Rhode Island Manufacturing Facility (ARIMF) and a payment with respect to sales of Soliris manufactured at Lonza facilities. In addition to Lonza, we have non-cancellable commitments of approximately $33,000 with other third party manufacturers. Contingent Liabilities We are currently involved in various claims, lawsuits and legal proceedings. On a quarterly basis, we review the status of each significant matter and assess its potential financial exposure. If the potential loss from any claim, asserted or unasserted, or legal proceeding is considered probable and the amount can be reasonably estimated, we accrue a liability for the estimated loss. Because of uncertainties related to claims and litigation, accruals are based on our best estimates based on available information. On a periodic basis, as additional information becomes available, or based on specific events such as the outcome of litigation or settlement of claims, we may reassess the potential liability related to these matters and may revise these estimates, which could result in a material adverse adjustment to our operating results. We have in the past received, and may in the future receive, notices from third parties claiming that their patents may be infringed by the development, manufacture or sale of Soliris. Under the guidance of ASC 450, Contingencies, we record a royalty accrual based on our best estimate of the fair value percent of net sales of Soliris that we could be required to pay the owners of patents for technology used in the manufacture and sale of Soliris. A costly license, or inability to obtain a necessary license, could have a material adverse effect on our financial results. In May 2015, we received a subpoena in connection with an investigation by the Enforcement Division of the U.S. Securities and Exchange Commission (SEC) requesting information related to our grant-making activities and compliance with the Foreign Corrupt Practices Act (FCPA) in various countries. In addition, in October 2015, Alexion received a request from the U.S. Department of Justice (DOJ) for the voluntary production of documents and other information pertaining to Alexion's compliance with FCPA. The SEC and DOJ also seek information related to Alexion’s recalls of specific lots of Soliris and related securities disclosures. Alexion is cooperating with these investigations. At this time, Alexion is unable to predict the duration, scope or outcome of these investigations. While it is possible that a loss related to these matters may be incurred, given the ongoing nature of these investigations, management cannot reasonably estimate the potential magnitude of such loss or range of loss, if any. Several securities class action lawsuits have been filed against the Company and former officers in federal district court alleging violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, 15 U.S.C. § 78j(b), and Rule 10b-5, promulgated thereunder, alleging that defendants made misstatements and/or omissions concerning the Company’s sales of Soliris. On November 17, 2016, a shareholder filed a putative class action in the U.S. District Court for the Southern District of New York. While the litigation was in the early stages, and before defendants had responded to the complaint, on December 30, 2016 plaintiffs filed a notice of voluntary dismissal and dismissed all claims without prejudice. On December 29, 2016, a second shareholder filed a putative class action against the Company and certain former employees in the U.S. District Court for the District of Connecticut, alleging that defendants made misrepresentations and omissions about Soliris between February 10, 2014 and December 9, 2016. The litigation is in the early stages, and defendants have not yet responded to the complaint. Given the early stages of this litigation, management does not currently believe that a loss related to this matter is probable or that the potential magnitude of such loss or range of loss, if any, can be reasonably estimated. In December 2016, we received a subpoena from the U.S. Attorney’s Office for the District of Massachusetts requesting documents relating generally to our support of 501(c)(3) organizations that provide financial assistance to Medicare patients taking drugs sold by Alexion, Alexion’s provision of free drug to Medicare patients, and Alexion compliance policies and training materials concerning the anti-kickback statute or payments to any 501(c)(3) organization that provides financial assistance to Medicare patients. Other companies have disclosed similar inquiries. We are cooperating with this inquiry. In March 2013, we received a Warning Letter (Warning Letter) from the U.S. Food and Drug Administration (FDA) regarding compliance with current Good Manufacturing Practices (cGMP) at ARIMF. The Warning Letter followed receipt of a Form 483 Inspectional Observations by the FDA in connection with an FDA inspection that concluded in August 2012. The observations relate to commercial and clinical manufacture of Soliris at ARIMF. We responded to the Warning Letter in a letter to the FDA dated in April 2013. As previously disclosed, the FDA issued Form 483s in August 2014 and August 2015 related to observations at ARIMF and the inspectional observations from the August 2014 and 2015 Form 483s have since been closed out by the FDA. During July 2016, the FDA completed a routine inspection at ARIMF and have since confirmed receipt of our responses to the inspectional observations included in the Form 483 received during that inspection. The observations are inspectional and do not represent a final FDA determination of compliance. We continue to manufacture products, including Soliris, in this facility. While the resolution of the issues raised in the Warning Letter is difficult to predict, we do not currently believe a loss related to this matter is probable or that the potential magnitude of such loss or range of loss, if any, can be reasonably estimated.

Restructuring

9 Months Ended

Sep. 30, 2016

Restructuring Cost and Reserve [Line Items]

Restructuring and Related Activities Disclosure [Text Block]

Restructuring

In connection with the acquisition and integration of Synageva in 2015, we recorded restructuring charges of $3,149 and $13,470 for the three and nine months ended September 30, 2015, respectively, primarily related to employee costs. Synageva restructuring charges were not material for the three and nine months ended September 30, 2016.

In the fourth quarter 2014, we announced plans to relocate our European headquarters from Lausanne to Zurich, Switzerland. The relocation of our European headquarters supports our operational needs based on growth in the European region. During the three and nine months ended September 30, 2016, we incurred additional restructuring costs of $377 and $2,392, respectively, as compared to $4,312 and $17,267, for the three and nine months ended September 30, 2015, respectively.

The following table presents a reconciliation of the restructuring reserve recorded within accrued expenses on the Company's condensed consolidated balance sheet for the three and nine months ended September 30, 2016:



	Three months ended September 30, 2016											Nine months ended September 30, 2016
	Employee Separation Costs		Contract Termination Costs			Other Costs			Total			Employee Separation Costs			Contract Termination Costs			Other Costs			Total
Liability, beginning of period	$	999	$	1,333		$	96		$	2,428		$	6,390		$	682		$	169		$	7,241
Restructuring expenses	—		—			564			564			—			35			1,456			1,491
Cash settlements	—		(335		)	(495		)	(830		)	(4,343		)	(1,017		)	(1,460		)	(6,820		)
Adjustments to previous estimates	—		—			—			—			(1,048		)	1,298			—			250
Liability, end of period	$	999	$	998		$	165		$	2,162		$	999		$	998		$	165		$	2,162

Acquisitions (Tables)

9 Months Ended

Sep. 30, 2016

Business Combinations [Abstract]

Schedule of Business Acquisitions, by Acquisition

The aggregate consideration to acquire Synageva consisted of:



Stock consideration	$	4,917,810
Cash consideration	4,565,524
Total purchase price	$	9,483,334

Schedule of Recognized Identified Assets Acquired and Liabilities Assumed

The following table summarizes the estimated fair values of assets acquired and liabilities assumed:



Cash	$	626,217
Inventory	23,880
In-process research and development (IPR&D)	4,236,000
Deferred tax liabilities, net	(159,991		)
Other assets and liabilities	(26,143		)
Net assets acquired	4,699,963
Goodwill	4,783,371
Total purchase price	$	9,483,334

Business Acquisition, Pro Forma Information



	Three months ended			Nine months ended
	September 30, 2015			September 30, 2015
Pro forma revenue	$	666,637		$	1,905,388
Pro forma net loss	(177,854		)	(47,565		)
Loss per common share
Basic	$	(0.79	)	$	(0.21	)
Diluted	$	(0.79	)	$	(0.21	)

Schedule of Acquisition Related Costs

Acquisition-related costs associated with our business combinations for the three and nine months ended September 30, 2016 and 2015 include the following:



	Three months ended				Nine months ended
	September 30,				September 30,
	2016		2015		2016		2015
Transaction costs ⁽¹⁾	$	—	$	—	$	375	$	26,799
Integration costs	—		6,075		1,938		9,053
	$	—	$	6,075	$	2,313	$	35,852

(1) Transaction costs include investment advisory, legal, and accounting fees

Inventories (Tables)

9 Months Ended

Sep. 30, 2016

Inventory, Net [Abstract]

Schedule of Inventory, Current

The components of inventory are as follows:



	September 30,		December 31,
	2016		2015
Raw materials	$	17,005	$	17,924
Work-in-process	192,279		180,324
Finished goods	153,774		91,626
	$	363,058	$	289,874

Intangible Assets and Goodwill (Tables)

9 Months Ended

Sep. 30, 2016

Goodwill and Intangible Assets Disclosure [Abstract]

Schedule of Intangible Assets and Goodwill

The following table summarizes the carrying amount of our intangible assets and goodwill, net of accumulated amortization:



		September 30, 2016							December 31, 2015
	Estimated Life (years)	Cost		Accumulated Amortization			Net		Cost		Accumulated Amortization			Net
Licenses	6-8	$	28,507	$	(28,507	)	$	—	$	28,507	$	(28,504	)	$	3
Patents	7	10,517		(10,517		)	—		10,517		(10,517		)	—
Purchased technology	6-16	4,710,495		(358,769		)	4,351,726		4,708,495		(116,584		)	4,591,911
Acquired IPR&D	Indefinite	116,000		—			116,000		116,000		—			116,000
Total		$	4,865,519	$	(397,793	)	$	4,467,726	$	4,863,519	$	(155,605	)	$	4,707,914
Goodwill	Indefinite	$	5,040,345	$	(2,901	)	$	5,037,444	$	5,050,786	$	(2,901	)	$	5,047,885

Schedule of Goodwill [Table Text Block]

The following table summarizes the changes in the carrying amount of goodwill:



Balance at December 31, 2015	$	5,047,885
Change in goodwill associated with prior acquisition	(10,441		)
Balance at September 30, 2016	$	5,037,444

Earnings Per Common Share (Tables)

9 Months Ended

Sep. 30, 2016

Earnings Per Common Share [Abstract]

Schedule Of Basic And Diluted Earnings Per Share

The following table summarizes the calculation of basic and diluted EPS for the three and nine months ended September 30, 2016 and 2015:



	Three months ended					Nine months ended
	September 30,					September 30,
	2016		2015			2016		2015
Net income (loss) used for basic and diluted calculation	$	94,338	$	(183,757	)	$	306,564	$	77,781
Shares used in computing earnings per common share—basic	224,180		226,228			224,454		209,373
Weighted-average effect of dilutive securities:
Stock awards	1,908		—			2,106		2,435
Shares used in computing earnings per common share—diluted	226,088		226,228			226,560		211,808
Earnings (loss) per common share:
Basic	$	0.42	$	(0.81	)	$	1.37	$	0.37
Diluted	$	0.42	$	(0.81	)	$	1.35	$	0.37

Marketable Securities (Tables)

9 Months Ended

Sep. 30, 2016

Investments, Debt and Equity Securities [Abstract]

Schedule of Available-for-sale Securities Reconciliation [Table Text Block]



	September 30, 2016
	Amortized Cost		Gross Unrealized Holding Gains		Gross Unrealized Holding Losses			Estimated Fair Value
Commercial paper	$	238,092	$	—	$	—		$	238,092
Corporate bonds	188,009		32		(237		)	187,804
Municipal bonds	155,421		1		(116		)	155,306
Other government-related obligations:
U.S.	30,503		—		(20		)	30,483
Foreign	133,530		4		(105		)	133,429
Bank certificates of deposit	14,751		—		—			14,751
Total available-for-sale debt securities	$	760,306	$	37	$	(478	)	$	759,865
Equity securities	—		1,775		—			1,775
Total available-for-sale securities	$	760,306	$	1,812	$	(478	)	$	761,640



	December 31, 2015
	Amortized Cost Basis		Gross Unrealized Holding Gains		Gross Unrealized Holding Losses			Aggregate Fair Value
Commercial paper	$	254,396	$	—	$	—		$	254,396
Corporate bonds	133,062		23		(336		)	132,749
Municipal bonds	87,173		1		(63		)	87,111
Other government-related obligations:
U.S.	25,244		—		(94		)	25,150
Foreign	163,403		—		(504		)	162,899
Bank certificates of deposit	27,000		—		—			27,000
Total available-for-sale securities	$	690,278	$	24	$	(997	)	$	689,305

Available-for-sale Securities by Balance Sheet Location Classification [Table Text Block]

The fair values of available-for-sale securities by classification in the condensed consolidated balance sheet were as follows:



	September 30, 2016		December 31, 2015
Cash and cash equivalents	$	224,179	$	323,218
Marketable securities	537,461		366,087
	$	761,640	$	689,305

Investments Classified by Contractual Maturity Date [Table Text Block]

The fair values of available-for-sale debt securities at September 30, 2016, by contractual maturity, are summarized as follows:



	September 30, 2016
Due in one year or less	$	508,813
Due after one year through three years	251,052
	$	759,865

Derivative Instruments and Hedging Activities (Tables)

9 Months Ended

Sep. 30, 2016

Derivative Instruments and Hedging Activities [Abstract]

Schedule of Other Comprehensive Income and Earnings from Foreign Exchange Contracts



	Three months ended						Nine months ended
	September 30,						September 30,
	2016			2015			2016			2015
Foreign Exchange Contracts:
Gain (loss) recognized in AOCI, net of tax	$	(10,402	)	$	10,206		$	(50,191	)	$	81,794
Gain reclassified from AOCI to net product sales (effective portion), net of tax	$	8,237		$	25,842		$	33,154		$	78,959
Gain (loss) reclassified from AOCI to other income and expense (ineffective portion), net of tax	$	—		$	(328	)	$	—		$	1,003
Interest Rate Contracts:
Gain (loss) recognized in AOCI, net of tax	$	2,517		$	—		$	(1,178	)	$	—
Loss reclassified from AOCI to interest expense, net of tax	$	(218	)	$	—		$	(218	)	$	—

Schedule of Fair Value of Outstanding Derivatives

The following tables summarize the fair value of outstanding derivatives at September 30, 2016 and December 31, 2015:



	September 30, 2016
	Asset Derivatives			Liability Derivatives
	Balance Sheet Location	Fair Value		Balance Sheet Location	Fair Value
Derivatives designated as hedging instruments:
Foreign exchange forward contracts	Prepaid expenses and other current assets	$	48,014	Other current liabilities	$	25,831
Foreign exchange forward contracts	Other assets	31,122		Other liabilities	38,392
Interest rate contracts	Prepaid expenses and other current assets	229		Other current liabilities	946
Interest rate contracts	Other assets	—		Other liabilities	797
Derivatives not designated as hedging instruments:
Foreign exchange forward contracts	Prepaid expenses and other current assets	2,306		Other current liabilities	9,113
Total fair value of derivative instruments		$	81,671		$	75,079



	December 31, 2015
	Asset Derivatives			Liability Derivatives
	Balance Sheet Location	Fair Value		Balance Sheet Location	Fair Value
Derivatives designated as hedging instruments:
Foreign exchange forward contracts	Prepaid expenses and other current assets	$	85,058	Other current liabilities	$	1,491
Foreign exchange forward contracts	Other assets	66,309		Other liabilities	4,773
Derivatives not designated as hedging instruments:
Foreign exchange forward contracts	Prepaid expenses and other current assets	6,687		Other current liabilities	4,157
Total fair value of derivative instruments		$	158,054		$	10,421

Offsetting Assets and Liabilities

The following tables summarize the potential effect on our condensed consolidated balance sheets of offsetting our foreign exchange forward contracts and interest rate contracts subject to such provisions:



	September 30, 2016
									Gross Amounts Not Offset in the Condensed Consolidated Balance Sheet
Description	Gross Amounts of Recognized Assets/Liabilities			Gross Amounts Offset in the Condensed Consolidated Balance Sheet		Net Amounts of Assets/Liabilities Presented in the Condensed Consolidated Balance Sheet			Derivative Financial Instruments			Cash Collateral Received (Pledged)		Net Amount
Derivative assets	$	81,671		$	—	$	81,671		$	(49,423	)	$	—	$	32,248
Derivative liabilities	(75,079		)	—		(75,079		)	49,423			—		(25,656		)



	December 31, 2015
									Gross Amounts Not Offset in the Condensed Consolidated Balance Sheet
Description	Gross Amounts of Recognized Assets/Liabilities			Gross Amounts Offset in the Condensed Consolidated Balance Sheet		Net Amounts of Assets/Liabilities Presented in the Condensed Consolidated Balance Sheet			Derivative Financial Instruments			Cash Collateral Received (Pledged)		Net Amount
Derivative assets	$	158,054		$	—	$	158,054		$	(10,421	)	$	—	$	147,633
Derivative liabilities	(10,421		)	—		(10,421		)	10,421			—		—

Other Comprehensive Income and Accumulated Other Comprehensive Income (Tables)

9 Months Ended

Sep. 30, 2016

Accumulated Other Comprehensive Income [Abstract]

Schedule of Accumulated Other Comprehensive Income (Loss)

The following tables summarize the changes in AOCI, by component, for the nine months ended September 30, 2016 and 2015:



	Defined Benefit Pension Plans			Unrealized Gains (Losses) from Marketable Securities			Unrealized Gains (Losses) from Hedging Activities			Foreign Currency Translation Adjustment			Total Accumulated Other Comprehensive Income (Loss)
Balances, December 31, 2015	$	(9,589	)	$	(785	)	$	92,670		$	(19,995	)	$	62,301
Other comprehensive income before reclassifications	1,003			1,893			(51,369		)	2,609			$	(45,864	)
Amounts reclassified from other comprehensive income	222			(340		)	(32,936		)	—			$	(33,054	)
Net other comprehensive income (loss)	1,225			1,553			(84,305		)	2,609			(78,918		)
Balances, September 30, 2016	$	(8,364	)	$	768		$	8,365		$	(17,386	)	$	(16,617	)



	Defined Benefit Pension Plans			Unrealized Gains (Losses) from Marketable Securities			Unrealized Gains (Losses) from Hedging Activities			Foreign Currency Translation Adjustment			Total Accumulated Other Comprehensive Income (Loss)
Balances, December 31, 2014	$	(16,570	)	$	(234	)	$	87,308		$	(13,719	)	$	56,785
Other comprehensive income before reclassifications	1,394			412			81,794			(6,065		)	77,535
Amounts reclassified from other comprehensive income	93			(23		)	(79,962		)	—			(79,892		)
Net other comprehensive income (loss)	1,487			389			1,832			(6,065		)	(2,357		)
Balances, September 30, 2015	$	(15,083	)	$	155		$	89,140		$	(19,784	)	$	54,428

Reclassification out of Accumulated Other Comprehensive Income

The table below provides details regarding significant reclassifications from AOCI during the three and nine months ended September 30, 2016 and 2015:



Details about Accumulated Other Comprehensive Income Components	Amount Reclassified From Accumulated Other Comprehensive Income during the three months ended September 30,						Amount Reclassified From Accumulated Other Comprehensive Income during the nine months ended September 30,						Affected Line Item in the Condensed Consolidated Statements of Operations
	2016			2015			2016			2015
Unrealized Gains (Losses) from Hedging Activity
Foreign exchange contracts (effective portion)	$	12,769		$	29,534		$	51,254		$	90,240		Net product sales
Foreign exchange contracts (ineffective portion)	—			(375		)	—			1,146			Foreign currency (loss) gain
Interest rate contracts	(344		)	—			(344		)	—			Interest expense
	12,425			29,159			50,910			91,386
	(4,406		)	(3,645		)	(17,974		)	(11,424		)	Income tax provision
	$	8,019		$	25,514		$	32,936		$	79,962
Unrealized Gains (Losses) from Marketable Securities
Realized gains on sale of securities	$	647		$	—		$	536		$	35		Investment income
	647			—			536			35
	(237		)	—			(196		)	(12		)	Income tax provision
	$	410		$	—		$	340		$	23
Defined Benefit Pension Plans
Amortization of prior service costs and actuarial losses	$	(117	)	$	(313	)	$	(346	)	$	(939	)	(a)
Other	—			821			—			821			(a)
	(117		)	508			(346		)	(118		)
	42			(107		)	124			25			Income tax provision
	$	(75	)	$	401		$	(222	)	$	(93	)

(a) This AOCI component is included in the computation of net periodic pension benefit cost (see Note 15 for additional details).

Fair Value Measurement (Tables)

9 Months Ended

Sep. 30, 2016

Fair Value Disclosures [Abstract]

Schedule Of Assets And Liabilites Measured At Fair Value



		Fair Value Measurement at September 30, 2016
Balance Sheet Classification	Type of Instrument	Total		Level 1		Level 2		Level 3
Cash equivalents	Institutional money market funds	$	83,864	$	—	$	83,864	$	—
Cash equivalents	Commercial paper	$	96,765	$	—	$	96,765	$	—
Cash equivalents	Corporate bonds	$	6,003	$	—	$	6,003	$	—
Cash equivalents	Municipal bonds	$	93,659	$	—	$	93,659	$	—
Cash equivalents	Bank certificates of deposit	$	1,750	$	—	$	1,750	$	—
Cash equivalents	Other government-related obligations	$	26,002	$	—	$	26,002	$	—
Marketable securities	Mutual funds	$	13,421	$	13,421	$	—	$	—
Marketable securities	Commercial paper	$	141,327	$	—	$	141,327	$	—
Marketable securities	Corporate bonds	$	181,801	$	—	$	181,801	$	—
Marketable securities	Municipal bonds	$	61,647	$	—	$	61,647	$	—
Marketable securities	Other government-related obligations	$	137,910	$	—	$	137,910	$	—
Marketable securities	Bank certificates of deposit	$	13,001	$	—	$	13,001	$	—
Marketable securities	Equity securities	$	1,775	$	1,775	$	—	$	—
Prepaid expenses and other current assets	Foreign exchange forward contracts	$	50,320	$	—	$	50,320	$	—
Other assets	Foreign exchange forward contracts	$	31,122	$	—	$	31,122	$	—
Other current liabilities	Foreign exchange forward contracts	$	34,944	$	—	$	34,944	$	—
Other liabilities	Foreign exchange forward contracts	$	38,392	$	—	$	38,392	$	—
Prepaid expenses and other current assets	Interest rate contracts	$	229	$	—	$	229	$	—
Other current liabilities	Interest rate contracts	$	946	$	—	$	946	$	—
Other liabilities	Interest rate contracts	$	797	$	—	$	797	$	—
Current portion of contingent consideration	Acquisition-related contingent consideration	$	81,848	$	—	$	—	$	81,848
Contingent consideration	Acquisition-related contingent consideration	$	126,056	$	—	$	—	$	126,056



		Fair Value Measurement at December 31, 2015
Balance Sheet Classification	Type of Instrument	Total		Level 1		Level 2		Level 3
Cash equivalents	Institutional money market funds	$	179,898	$	—	$	179,898	$	—
Cash equivalents	Commercial paper	$	192,418	$	—	$	192,418	$	—
Cash equivalents	Corporate bonds	$	12,250	$	—	$	12,250	$	—
Cash equivalents	Municipal bonds	$	60,001	$	—	$	60,001	$	—
Cash equivalents	Other government-related obligations	$	31,549	$	—	$	31,549	$	—
Cash equivalents	Bank certificates of deposit	$	27,000	$	—	$	27,000	$	—
Marketable securities	Mutual funds	$	8,817	$	8,817	$	—	$	—
Marketable securities	Commercial paper	$	61,978	$	—	$	61,978	$	—
Marketable securities	Corporate bonds	$	120,499	$	—	$	120,499	$	—
Marketable securities	Municipal bonds	$	27,110	$	—	$	27,110	$	—
Marketable securities	Other government-related obligations	$	156,500	$	—	$	156,500	$	—
Prepaid expenses and other current assets	Foreign exchange forward contracts	$	91,745	$	—	$	91,745	$	—
Other assets	Foreign exchange forward contracts	$	66,309	$	—	$	66,309	$	—
Other current liabilities	Foreign exchange forward contracts	$	5,648	$	—	$	5,648	$	—
Other liabilities	Foreign exchange forward contracts	$	4,773	$	—	$	4,773	$	—
Current portion of contingent consideration	Acquisition-related contingent consideration	$	55,804	$	—	$	—	$	55,804
Contingent consideration	Acquisition-related contingent consideration	$	121,424	$	—	$	—	$	121,424

Schedule Of Acquisition-Related Contingent Consideration

The following table represents a roll-forward of our acquisition-related contingent consideration:



	Nine months ended
	September 30, 2016
Balance at December 31, 2015	$	(177,228	)
Changes in fair value	(30,676		)
Balance at September 30, 2016	$	(207,904	)

Income Taxes (Tables)

9 Months Ended

Sep. 30, 2016

Income Tax Disclosure [Abstract]

Schedule of Income Tax Provision and Effective Tax Rate

The following table provides a comparative summary of our income tax provision and effective tax rate for the three and nine months ended September 30, 2016 and 2015:



	Three months ended						Nine months ended
	September 30,						September 30,
	2016			2015			2016			2015
Provision for income taxes	$	63,776		$	323,116		$	165,113		$	345,815
Effective tax rate	40.3		%	231.9		%	35.0		%	81.6		%

Employee Benefit Plans (Tables)

9 Months Ended

Sep. 30, 2016

Compensation and Retirement Disclosure [Abstract]

Schedule of Components of Net Periodic Benefit Costs

The components of net periodic benefit cost are as follows:



	Three months ended						Nine months ended
	September 30,						September 30,
	2016			2015			2016			2015
Service cost	$	2,113		$	2,380		$	6,211		$	7,241
Interest cost	56			179			172			551
Expected return on plan assets	(167		)	(248		)	(496		)	(756		)
Employee contributions	(448		)	(442		)	(1,203		)	(1,342		)
Amortization	117			313			346			939
Other	—			(821		)	—			(821		)
	$	1,671		$	1,361		$	5,030		$	5,812

Restructuring (Tables)

9 Months Ended

Sep. 30, 2016

Restructuring Cost and Reserve [Line Items]

Restructuring and Related Costs [Table Text Block]



	Three months ended September 30, 2016											Nine months ended September 30, 2016
	Employee Separation Costs		Contract Termination Costs			Other Costs			Total			Employee Separation Costs			Contract Termination Costs			Other Costs			Total
Liability, beginning of period	$	999	$	1,333		$	96		$	2,428		$	6,390		$	682		$	169		$	7,241
Restructuring expenses	—		—			564			564			—			35			1,456			1,491
Cash settlements	—		(335		)	(495		)	(830		)	(4,343		)	(1,017		)	(1,460		)	(6,820		)
Adjustments to previous estimates	—		—			—			—			(1,048		)	1,298			—			250
Liability, end of period	$	999	$	998		$	165		$	2,162		$	999		$	998		$	165		$	2,162

Basis of Presentation and Principles Of Consolidation Basis of Presentation and Principles Of Consolidation (Details) - USD ($) $ in Thousands	3 Months Ended	9 Months Ended
	Sep. 30, 2016	Sep. 30, 2016	Dec. 31, 2015
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Effective Income Tax Rate Reconciliation, Share-based Compensation, Excess Tax Benefit, Amount	$ 2,249	$ 7,366
New Accounting Pronouncement, Early Adoption, Effect [Member] \| Other Current Assets [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Deferred Finance Costs, Net			$ 8,635
New Accounting Pronouncement, Early Adoption, Effect [Member] \| Other Noncurrent Assets [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Deferred Finance Costs, Net			26,714
Accounting Standards Update 2016-09 [Member] \| New Accounting Pronouncement, Early Adoption, Effect [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Deferred Tax Asset			237,850
Retained Earnings [Member] \| Accounting Standards Update 2016-09 [Member] \| New Accounting Pronouncement, Early Adoption, Effect [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Cumulative Effect of New Accounting Principle			$ 237,850

Acquisitions Total Consideration Transferred (Details) - USD ($) $ in Thousands		9 Months Ended
	Jun. 22, 2015	Sep. 30, 2016	Sep. 30, 2015
Business Acquisition [Line Items]
Stock consideration		$ 0	$ 4,917,810
Synageva BioPharma Corp.
Business Acquisition [Line Items]
Stock consideration	$ 4,917,810
Cash consideration	4,565,524
Total purchase price	$ 9,483,334

Acquisitions Purchase Price Allocation to Assets Acquired and Liabilities Assumed (Details) - USD ($) $ in Thousands	Sep. 30, 2016	Dec. 31, 2015	Jun. 22, 2015
Business Acquisition [Line Items]
Goodwill	$ 5,037,444	$ 5,047,885
Synageva BioPharma Corp.
Business Acquisition [Line Items]
Cash			$ 626,217
Inventory			23,880
In-process research and development (IPR&D)			4,236,000
Deferred tax liabilities, net			(159,991)
Other assets and liabilities			(26,143)
Net assets acquired			4,699,963
Goodwill			4,783,371
Total purchase price			$ 9,483,334

Acquisitions Pro Forma Financial Information of Combined Results of Operations (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended	9 Months Ended
	Sep. 30, 2015	Sep. 30, 2015
Business Combinations [Abstract]
Pro forma revenue	$ 666,637	$ 1,905,388
Pro forma net loss	$ (177,854)	$ (47,565)
Basic (dollars per share)	$ (0.79)	$ (0.21)
Diluted (dollars per share)	$ (0.79)	$ (0.21)

Acquisitions Acquisition Related Costs (Details) - USD ($)
$ in Thousands

3 Months Ended

9 Months Ended

Sep. 30, 2016

Sep. 30, 2015

Sep. 30, 2016

Sep. 30, 2015

Business Acquisition [Line Items]

Transaction costs

^[1]

$ 0

$ 375

$ 26,799

Integration costs

6,075

1,938

9,053

Acquisition related costs

$ 0

$ 6,075

$ 2,313

$ 35,852

[1]	Transaction costs include investment advisory, legal, and accounting fees

Acquisitions Narrative (Details) - USD ($)			3 Months Ended		9 Months Ended
Acquisitions Narrative (Details) - USD ($)	Jun. 22, 2015	May 06, 2015	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015	May 05, 2015
Business Acquisition [Line Items]
Change in goodwill associated with prior acquisition					$ (10,441,000)
Net income (loss)			$ 94,338,000	$ (183,757,000)	306,564,000	$ 77,781,000
Restructuring Charges			$ 564,000		$ 1,491,000
Synageva BioPharma Corp.
Business Acquisition [Line Items]
Payments to acquire business	$ 4,565,524,000
Number of shares	26,125,000
Consideration transferred, net of cash acquired	$ 8,860,000,000
Share price (dollars per share)	$ 188.24
Inventory	$ 23,880,000
In-process research and development (IPR&D)	$ 4,236,000,000
Weighted Average Cost of Capital	10.00%
Deferred tax liabilities, net	$ 159,991,000
Deferred Tax Liabilities, Net	602,887,000
Deferred Tax Assets, Net	$ 442,896,000
Business Combination, Separately Recognized Transactions, Expenses and Losses Recognized				53,721,000		58,356,000
Restructuring Charges				3,149,000		13,470,000
Scenario, Previously Reported \| Synageva BioPharma Corp.
Business Acquisition [Line Items]
Payments to acquire business		$ 115
Number of shares		0.6581
Consideration transferred, net of cash acquired		$ 8,400,000,000
Share price (dollars per share)							$ 168.55
Stock Based Compensation Expense
Business Acquisition [Line Items]
Net income (loss)				33,150,000
Stock Based Compensation Expense \| Synageva BioPharma Corp.
Business Acquisition [Line Items]
Net income (loss)				127,290,000
Acquisition Related and Restructuring Costs
Business Acquisition [Line Items]
Net income (loss)				$ 9,223,000		49,367,000
Acquisition Related and Restructuring Costs \| Synageva BioPharma Corp.
Business Acquisition [Line Items]
Net income (loss)						$ 62,071,000

Inventories (Details) - USD ($) $ in Thousands	Sep. 30, 2016	Dec. 31, 2015	Jun. 22, 2015
Inventory [Line Items]
Inventory, Raw Materials	$ 17,005	$ 17,924
Inventory, Work in Process	192,279	180,324
Inventory, Finished Goods	153,774	91,626
Inventory, Net	$ 363,058	$ 289,874
Synageva BioPharma Corp.
Inventory [Line Items]
Inventory			$ 23,880

Intangible Assets and Goodwill (Schedule of Intangible Assets and Goodwill) (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2016	Dec. 31, 2015
Finite-Lived Intangible Assets [Line Items]
Intangible Assets, Cost	$ 4,865,519	$ 4,863,519
Intangible Assets, Accumulated Amortization	(397,793)	(155,605)
Goodwill, Gross	5,040,345	5,050,786
Goodwill, Accumulated Amortization	(2,901)	(2,901)
Intangible assets	4,467,726	4,707,914
Goodwill	5,037,444	5,047,885
Licensing Agreements [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Gross	28,507	28,507
Finite-Lived Intangible Assets, Accumulated Amortization	(28,507)	(28,504)
Licenses, patents and purchased technology	$ 0	3
Licensing Agreements [Member] \| Minimum [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Asset, Useful Life	6 years
Licensing Agreements [Member] \| Maximum [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Asset, Useful Life	8 years
Patents [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Asset, Useful Life	7 years
Finite-Lived Intangible Assets, Gross	$ 10,517	10,517
Finite-Lived Intangible Assets, Accumulated Amortization	(10,517)	(10,517)
Licenses, patents and purchased technology	0	0
Purchased Technology [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Gross	4,710,495	4,708,495
Finite-Lived Intangible Assets, Accumulated Amortization	(358,769)	(116,584)
Licenses, patents and purchased technology	$ 4,351,726	4,591,911
Purchased Technology [Member] \| Minimum [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Asset, Useful Life	6 years
Purchased Technology [Member] \| Maximum [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Asset, Useful Life	16 years
Acquired IPRD [Member]
Finite-Lived Intangible Assets [Line Items]
Indefinite-Lived Intangible Assets, Accumulated Amortization	$ 0	0
Acquired in-process research and development	$ 116,000	$ 116,000

Intangible Assets and Goodwill (Narrative) (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015	Jun. 22, 2015
Goodwill [Line Items]
Amortization of Intangible Assets	$ 82,035	$ 36,619	$ 242,188	$ 36,640
Finite-Lived Intangible Assets, Amortization Expense, Remainder of Fiscal Year	80,035		80,035
Finite-Lived Intangible Assets, Amortization Expense, Next Twelve Months	320,142		320,142
Finite-Lived Intangible Assets, Amortization Expense, Year Two	320,142		320,142
Finite-Lived Intangible Assets, Amortization Expense, Year Three	320,142		320,142
Finite-Lived Intangible Assets, Amortization Expense, Year Four	320,142		320,142
Finite-Lived Intangible Assets, Amortization Expense, Year Five	$ 320,142		$ 320,142
Synageva BioPharma Corp.
Goodwill [Line Items]
In-process research and development (IPR&D)					$ 4,236,000

Intangible Assets and Goodwill Schedule of Changes in the Carrying Amount of Goodwill (Details) $ in Thousands	9 Months Ended
	Sep. 30, 2016 USD ($)
Goodwill [Roll Forward]
Goodwill, beginning balance	$ 5,047,885
Change in goodwill associated with prior acquisition	(10,441)
Goodwill, ending balance	$ 5,037,444

Debt (Details) - USD ($) $ in Thousands	1 Months Ended	3 Months Ended		9 Months Ended
Debt (Details) - USD ($) $ in Thousands	Dec. 31, 2016	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015	Jan. 04, 2017	Jun. 22, 2015
Debt Instrument [Line Items]
Amortization of Financing Costs		$ 2,382	$ 2,513	$ 7,278	$ 3,864
Repayments of Long-term Debt	$ 200,000			175,000	57,500
Proceeds from issuance of long-term debt				0	$ 3,500,000
Credit Agreement [Member]
Debt Instrument [Line Items]
Payments of Financing Costs				45,492
Senior Secured Term Loan [Member] \| Credit Agreement [Member]
Debt Instrument [Line Items]
Debt instrument, principal amount							$ 3,500,000
Debt Instrument, quarterly payment as a percent of total borrowings							1.25%
Outstanding debt		3,281,250		3,281,250		$ 3,081,250
Line of Credit [Member] \| Credit Agreement [Member]
Debt Instrument [Line Items]
Line of credit facility, maximum borrowing capacity							$ 500,000
Letters of credit, amount outstanding		14,632		14,632
Line of credit facility, borrowing availability		$ 485,368		$ 485,368
Letter of Credit [Member] \| Credit Agreement [Member]
Debt Instrument [Line Items]
Sublimit for letter of credit for working capital requirements and other general corporate purposes							100,000
Bridge Loan [Member] \| Credit Agreement [Member]
Debt Instrument [Line Items]
Sublimit for letter of credit for working capital requirements and other general corporate purposes							$ 25,000

Earnings Per Common Share (Summary Of Calculation Of Basic And Diluted Earnings Per Share) (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Earnings Per Common Share [Abstract]
Net income used for basic and diluted calculation	$ 94,338	$ (183,757)	$ 306,564	$ 77,781
Shares used in computing earnings per common share—basic	224,180	226,228	224,454	209,373
Stock awards	1,908	0	2,106	2,435
Shares used in computing earnings per common share-diluted	226,088	226,228	226,560	211,808
Earnings Per Share, Basic	$ 0.42	$ (0.81)	$ 1.37	$ 0.37
Earnings Per Share, Diluted	$ 0.42	$ (0.81)	$ 1.35	$ 0.37

- Definition

The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.

+ References + Details

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References + Details

Earnings Per Common Share (Narrative) (Details) - shares shares in Thousands	3 Months Ended	9 Months Ended
	Sep. 30, 2016	Sep. 30, 2016	Sep. 30, 2015
Earnings Per Share [Abstract]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	4,520	4,386	2,437

Marketable Securities (Summary of Securities Held) (Details) - USD ($) $ in Thousands	Sep. 30, 2016	Dec. 31, 2015
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	$ 760,306	$ 690,278
Gross Unrealized Holding Gains	1,812	24
Gross Unrealized Holding Losses	(478)	(997)
Estimated Fair Value	761,640	689,305
Debt Securities [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	760,306
Gross Unrealized Holding Gains	37
Gross Unrealized Holding Losses	(478)
Estimated Fair Value	759,865
Commercial Paper [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	238,092	254,396
Gross Unrealized Holding Gains	0	0
Gross Unrealized Holding Losses	0	0
Estimated Fair Value	238,092	254,396
Corporate Bond Securities [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	188,009	133,062
Gross Unrealized Holding Gains	32	23
Gross Unrealized Holding Losses	(237)	(336)
Estimated Fair Value	187,804	132,749
Municipal Bonds [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	155,421	87,173
Gross Unrealized Holding Gains	1	1
Gross Unrealized Holding Losses	(116)	(63)
Estimated Fair Value	155,306	87,111
US Government Agencies Debt Securities [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	30,503	25,244
Gross Unrealized Holding Gains	0	0
Gross Unrealized Holding Losses	(20)	(94)
Estimated Fair Value	30,483	25,150
Foreign Government Debt Securities [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	133,530	163,403
Gross Unrealized Holding Gains	4	0
Gross Unrealized Holding Losses	(105)	(504)
Estimated Fair Value	133,429	162,899
Certificates of Deposit [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	14,751	27,000
Gross Unrealized Holding Gains	0	0
Gross Unrealized Holding Losses	0	0
Estimated Fair Value	14,751	$ 27,000
Equity Securities [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	0
Gross Unrealized Holding Gains	1,775
Gross Unrealized Holding Losses	0
Estimated Fair Value	$ 1,775

Marketable Securities (Available-for-sale Investments by Classification in Balance Sheet) (Details) - USD ($) $ in Thousands	Sep. 30, 2016	Dec. 31, 2015
Schedule of Available-for-sale Securities [Line Items]
Available-for-sale securities	$ 761,640	$ 689,305
Cash and Cash Equivalents [Member]
Schedule of Available-for-sale Securities [Line Items]
Available-for-sale securities	224,179	323,218
Marketable Securities [Member]
Schedule of Available-for-sale Securities [Line Items]
Available-for-sale securities	$ 537,461	$ 366,087

Marketable Securities (Available-for-sale Debt Securities by Contractual Maturity) (Details) $ in Thousands	Sep. 30, 2016 USD ($)
Investments, Debt and Equity Securities [Abstract]
Due in one year or less	$ 508,813
Due after one year through three years	251,052
Estimated Fair Value	$ 759,865

Marketable Securities (Narrative) (Details) - USD ($) $ in Thousands	Sep. 30, 2016	Dec. 31, 2015
Investments, Debt and Equity Securities [Abstract]
Available-for-sale Securities, Continuous Unrealized Loss Position, Less than Twelve Months, Fair Value	$ 348,525	$ 293,947
Trading securities. fair value	$ 13,421	$ 8,817

Derivative Instruments and Hedging Activities (Narrative) (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015	Dec. 31, 2015
Designated as Hedging Instrument [Member]
Derivative [Line Items]
Foreign Exchange Forward Contracts Term			60 months
Not Designated as Hedging Instrument [Member]
Derivative [Line Items]
Foreign Exchange Forward Contracts Term			90 days
Gain (loss) in other income and expense	$ (2,528,000)	$ 2,676,000	$ (20,643,000)	$ 2,439,000
Foreign Exchange Forward [Member] \| Designated as Hedging Instrument [Member]
Derivative [Line Items]
Notional Amount of Derivative Instruments	1,902,227,000		1,902,227,000
Foreign Exchange Forward [Member] \| Not Designated as Hedging Instrument [Member]
Derivative [Line Items]
Notional Amount of Derivative Instruments	569,590,000		569,590,000
Derivative, fair value, net					$ 0
Senior Secured Term Loan [Member] \| Credit Agreement [Member] \| Interest Rate Swap One [Member]
Derivative [Line Items]
Derivative, amount of hedged item	$ 3,281,250,000		$ 3,281,250,000
Debt instrument, fixed rate (percent)	0.535%		0.535%
Senior Secured Term Loan [Member] \| Credit Agreement [Member] \| Interest Rate Swap Two [Member]
Derivative [Line Items]
Derivative, amount of hedged item	$ 656,250,000		$ 656,250,000
Debt instrument, fixed rate (percent)	0.98%		0.98%
Revenue \| Foreign Exchange Forward [Member] \| Designated as Hedging Instrument [Member]
Derivative [Line Items]
Estimated gains (losses) to be reclassified from other comprehenisve income in next 12 months			$ 22,182,000
Interest Expense \| Foreign Exchange Forward [Member] \| Designated as Hedging Instrument [Member]
Derivative [Line Items]
Estimated gains (losses) to be reclassified from other comprehenisve income in next 12 months			$ (717,000)

Derivative Instruments and Hedging Activities (Schedule Of Other Comprehensive Income And Earnings From Foreign Exchange Contracts) (Details) - Cash Flow Hedging [Member] - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Foreign Exchange Forward [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Gain (loss) recognized in AOCI, net of tax	$ (10,402)	$ 10,206	$ (50,191)	$ 81,794
Gain (loss) reclassified from AOCI to other income and expense (ineffective portion), net of tax	0	(328)	0	1,003
Foreign Exchange Forward [Member] \| Sales
Derivative Instruments, Gain (Loss) [Line Items]
Gain (loss) reclassified from AOCI to income (effective portion), net of tax	8,237	25,842	33,154	78,959
Interest Rate Contract [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Gain (loss) recognized in AOCI, net of tax	2,517	0	(1,178)	0
Interest Rate Contract [Member] \| Interest Expense
Derivative Instruments, Gain (Loss) [Line Items]
Gain (loss) reclassified from AOCI to income (effective portion), net of tax	$ (218)	$ 0	$ (218)	$ 0

Derivative Instruments and Hedging Activities (Schedule Of Fair Value Of Outstanding Derivatives) (Details) - USD ($) $ in Thousands	Sep. 30, 2016	Dec. 31, 2015
Interest Rate Contract [Member] \| Other Current Liabilities [Member] \| Designated as Hedging Instrument [Member]
Derivatives, Fair Value [Line Items]
Liability Derivatives, Fair Value	$ 946
Interest Rate Contract [Member] \| Other Noncurrent Assets [Member] \| Designated as Hedging Instrument [Member]
Derivatives, Fair Value [Line Items]
Asset Derivatives, Fair Value	0
Interest Rate Contract [Member] \| Other Noncurrent Liabilities [Member] \| Designated as Hedging Instrument [Member]
Derivatives, Fair Value [Line Items]
Liability Derivatives, Fair Value	797
Interest Rate Contract [Member] \| Prepaid Expenses and Other Current Assets [Member] \| Designated as Hedging Instrument [Member]
Derivatives, Fair Value [Line Items]
Asset Derivatives, Fair Value	229
Foreign Exchange Forward [Member]
Derivatives, Fair Value [Line Items]
Asset Derivatives, Fair Value	81,671	$ 158,054
Liability Derivatives, Fair Value	75,079	10,421
Foreign Exchange Forward [Member] \| Other Current Liabilities [Member] \| Designated as Hedging Instrument [Member]
Derivatives, Fair Value [Line Items]
Liability Derivatives, Fair Value	25,831	1,491
Foreign Exchange Forward [Member] \| Other Noncurrent Assets [Member] \| Designated as Hedging Instrument [Member]
Derivatives, Fair Value [Line Items]
Asset Derivatives, Fair Value	31,122	66,309
Foreign Exchange Forward [Member] \| Other Noncurrent Liabilities [Member] \| Designated as Hedging Instrument [Member]
Derivatives, Fair Value [Line Items]
Liability Derivatives, Fair Value	38,392	4,773
Foreign Exchange Forward [Member] \| Prepaid Expenses and Other Current Assets [Member] \| Designated as Hedging Instrument [Member]
Derivatives, Fair Value [Line Items]
Asset Derivatives, Fair Value	48,014	85,058
Foreign Exchange Forward [Member] \| Other Current Liabilities [Member] \| Not Designated as Hedging Instrument [Member]
Derivatives, Fair Value [Line Items]
Liability Derivatives, Fair Value	9,113	4,157
Foreign Exchange Forward [Member] \| Prepaid Expenses and Other Current Assets [Member] \| Not Designated as Hedging Instrument [Member]
Derivatives, Fair Value [Line Items]
Asset Derivatives, Fair Value	$ 2,306	$ 6,687

Derivative Instruments and Hedging Activities (Offsetting Assets and Liabilities) (Details) - Foreign Exchange Forward [Member] - USD ($) $ in Thousands	Sep. 30, 2016	Dec. 31, 2015
Derivative Asset, Fair Value, Amount Offset Against Collateral [Abstract]
Gross Amounts of Recognized Assets	$ 81,671	$ 158,054
Gross Amounts Offset in the Condensed Consolidated Balance Sheet	0	0
Amounts of Assets Presented in the Condensed Consolidated Balance Sheet	81,671	158,054
Derivative Financial Instruments	(49,423)	(10,421)
Cash Collateral Received	0	0
Net Amount	32,248	147,633
Derivative Liability, Fair Value, Amount Offset Against Collateral [Abstract]
Gross Amounts of Recognized Liabilities	(75,079)	(10,421)
Gross Amounts Offset in the Condensed Consolidated Balance Sheet	0	0
Amounts of Liabilities Presented in the Condensed Consolidated Balance Sheet	(75,079)	(10,421)
Derivative Financial Instruments	49,423	10,421
Cash Collateral Pledged	0	0
Net Amount	$ (25,656)	$ 0

Other Investments (Details) $ in Thousands	Sep. 30, 2016 USD ($)
Moderna LLC [Member]
Investment [Line Items]
Investment Owned, at Cost	$ 37,500

Stockholders' Equity (Details) - USD ($) $ in Thousands		3 Months Ended			9 Months Ended
Stockholders' Equity (Details) - USD ($) $ in Thousands	Jun. 22, 2015	Dec. 22, 2016	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015	May 06, 2015
Class of Stock [Line Items]
Treasury Stock, Shares, Acquired			536,000	556,000	2,864,000	1,022,000
Treasury Stock, Value, Acquired, Cost Method			$ 69,321	$ 91,820	$ 399,972	$ 175,383
Stock consideration					0	4,917,810
Payments of Stock Issuance Costs					$ 0	$ 4,053
Common Stock [Member]
Class of Stock [Line Items]
Stock Repurchase Program, Authorized Amount							$ 1,000,000
Subsequent Event [Member]
Class of Stock [Line Items]
Treasury Stock, Shares, Acquired		250,000
Treasury Stock, Value, Acquired, Cost Method		$ 30,695
Subsequent Event [Member] \| Common Stock [Member]
Class of Stock [Line Items]
Stock Repurchase Program, Remaining Authorized Repurchase Amount		$ 325,197
Synageva BioPharma Corp.
Class of Stock [Line Items]
Number of shares	26,125,000
Stock consideration	$ 4,917,810

Other Comprehensive Income and Accumulated Other Comprehensive Income (Changes in AOCI) (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Accumulated Other Comprehensive Income (Loss) [Roll Forward]
Beginning Balance			$ 62,301	$ 56,785
Other comprehensive income before reclassifications			(45,864)	77,535
Amounts reclassified from other comprehensive income			(33,054)	(79,892)
Other comprehensive (loss) income, net of tax	$ (17,311)	$ (8,088)	(78,918)	(2,357)
Ending Balance	(16,617)	54,428	(16,617)	54,428
Accumulated Defined Benefit Plans Adjustment [Member]
Accumulated Other Comprehensive Income (Loss) [Roll Forward]
Beginning Balance			(9,589)	(16,570)
Other comprehensive income before reclassifications			1,003	1,394
Amounts reclassified from other comprehensive income			222	93
Other comprehensive (loss) income, net of tax			1,225	1,487
Ending Balance	(8,364)	(15,083)	(8,364)	(15,083)
Accumulated Net Unrealized Investment Gain (Loss) [Member]
Accumulated Other Comprehensive Income (Loss) [Roll Forward]
Beginning Balance			(785)	(234)
Other comprehensive income before reclassifications			1,893	412
Amounts reclassified from other comprehensive income			(340)	(23)
Other comprehensive (loss) income, net of tax			1,553	389
Ending Balance	768	155	768	155
Accumulated Net Gain (Loss) from Designated or Qualifying Cash Flow Hedges [Member]
Accumulated Other Comprehensive Income (Loss) [Roll Forward]
Beginning Balance			92,670	87,308
Other comprehensive income before reclassifications			(51,369)	81,794
Amounts reclassified from other comprehensive income			(32,936)	(79,962)
Other comprehensive (loss) income, net of tax			(84,305)	1,832
Ending Balance	8,365	89,140	8,365	89,140
Accumulated Translation Adjustment [Member]
Accumulated Other Comprehensive Income (Loss) [Roll Forward]
Beginning Balance			(19,995)	(13,719)
Other comprehensive income before reclassifications			2,609	(6,065)
Amounts reclassified from other comprehensive income			0	0
Other comprehensive (loss) income, net of tax			2,609	(6,065)
Ending Balance	$ (17,386)	$ (19,784)	$ (17,386)	$ (19,784)

- Definition

Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.

+ References + Details

Other Comprehensive Income and Accumulated Other Comprehensive Income (Significant Reclassifications from AOCI) (Details) - USD ($)
$ in Thousands

3 Months Ended

9 Months Ended

Sep. 30, 2016

Sep. 30, 2015

Sep. 30, 2016

Sep. 30, 2015

Reclassification out of Accumulated Other Comprehensive Income [Line Items]

Net product sales

$ 798,524

$ 665,791

$ 2,251,495

$ 1,902,107

Foreign currency (loss) gain

(1,011)

2,795

(3,740)

1,755

Interest expense

(24,807)

(19,971)

(72,490)

(24,593)

Investment income

4,626

1,967

8,049

7,077

Income before income taxes

158,114

139,359

471,677

423,596

Income tax provision

(63,776)

(323,116)

(165,113)

(345,815)

Net income (loss)

94,338

(183,757)

306,564

77,781

Accumulated Net Gain (Loss) from Designated or Qualifying Cash Flow Hedges [Member] | Reclassification out of Accumulated Other Comprehensive Income [Member]

Reclassification out of Accumulated Other Comprehensive Income [Line Items]

Net product sales

12,769

29,534

51,254

90,240

Foreign currency (loss) gain

(375)

1,146

Interest expense

(344)

Income before income taxes

12,425

29,159

50,910

91,386

Income tax provision

(4,406)

(3,645)

(17,974)

(11,424)

Net income (loss)

8,019

25,514

32,936

79,962

Accumulated Net Unrealized Investment Gain (Loss) [Member] | Reclassification out of Accumulated Other Comprehensive Income [Member]

Reclassification out of Accumulated Other Comprehensive Income [Line Items]

Investment income

647

536

Income before income taxes

647

536

Income tax provision

(237)

(196)

(12)

Net income (loss)

410

340

Accumulated Defined Benefit Plans Adjustment [Member] | Reclassification out of Accumulated Other Comprehensive Income [Member]

Reclassification out of Accumulated Other Comprehensive Income [Line Items]

Amortization of prior service costs and actuarial losses

^[1]

(117)

(313)

(346)

(939)

Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI, Pension and Other Postretirement Benefit Plans, for Net Gain (Loss), before Tax

^[1]

821

Income before income taxes

(117)

508

(346)

(118)

Income tax provision

(107)

124

Net income (loss)

$ (75)

$ 401

$ (222)

$ (93)

[1]	This AOCI component is included in the computation of net periodic pension benefit cost (see Note 15 for additional details).

Fair Value Measurement (Schedule Of Acquisition-Related Contingent Consideration) (Details) - USD ($) $ in Thousands	1 Months Ended	9 Months Ended
	Dec. 31, 2016	Sep. 30, 2016	Sep. 30, 2015
Fair Value Inputs, Liabilities, Quantitative Information [Line Items]
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, Low		$ 0
Business Combination, Contingent Consideration, Arrangements, Range of Outcomes, Value, High		826,000
Payment for Contingent Consideration		0	$ 50,000
Acquisition Related Contingent Consideration [Member]
Fair Value Inputs, Liabilities, Quantitative Information [Line Items]
Business Combination, Contingent Consideration, Liability		207,904
Acquisition Related Contingent Consideration [Member] \| Level 3 [Member]
Acquisition-Related Contingent Consideration [Roll Forward]
Balance at beginning of period		(177,228)
Change in fair value		(30,676)
Balance at end of period		$ (207,904)
Acquisition Related Contingent Consideration [Member] \| Minimum [Member] \| Level 3 [Member]
Fair Value Inputs, Liabilities, Quantitative Information [Line Items]
Fair Value Inputs, Cost of Debt		5.50%
Fair Value Inputs, Weighted Average Cost of Capital		10.00%
Acquisition Related Contingent Consideration [Member] \| Maximum [Member] \| Level 3 [Member]
Fair Value Inputs, Liabilities, Quantitative Information [Line Items]
Fair Value Inputs, Weighted Average Cost of Capital		21.00%
Subsequent Event [Member]
Fair Value Inputs, Liabilities, Quantitative Information [Line Items]
Payment for Contingent Consideration	$ 60,000

Income Taxes (Schedule of Income Tax Provision and Effective Tax Rate) (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Income Tax Disclosure [Abstract]
Provision for income taxes	$ 63,776	$ 323,116	$ 165,113	$ 345,815
Effective tax rate	40.30%	231.90%	35.00%	81.60%

Income Taxes (Narrative) (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
Income Taxes (Narrative) (Details) - USD ($) $ in Thousands	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Income Taxes [Line Items]
Income Tax, Book-Over-Tax Basis Change in Captive Foreign Partnership		$ 315,569
Income Tax Expense (Benefit)	$ 63,776	$ 323,116	$ 165,113	$ 345,815

Defined Benefit Plans (Schedule of Components of Net Periodic Benefit Cost) (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Compensation and Retirement Disclosure [Abstract]
Service cost	$ 2,113	$ 2,380	$ 6,211	$ 7,241
Interest cost	56	179	172	551
Expected return on plan assets	(167)	(248)	(496)	(756)
Employee contributions	(448)	(442)	(1,203)	(1,342)
Amortization	117	313	346	939
Defined Benefit Plan, Other Costs	0	(821)	0	(821)
Total net periodic benefit cost	$ 1,671	$ 1,361	$ 5,030	$ 5,812

Facility Lease Obligations (Details) - USD ($) $ in Thousands	1 Months Ended	9 Months Ended
	Nov. 30, 2012	Sep. 30, 2016	Dec. 31, 2015
Operating Leased Assets [Line Items]
Facility Lease Obligation, Noncurrent		$ 224,442	$ 151,307
CONNECTICUT \| Construction in Progress [Member]
Operating Leased Assets [Line Items]
Facility Lease Obligation		135,442	132,866
Minimum [Member] \| CONNECTICUT \| Construction in Progress [Member]
Operating Leased Assets [Line Items]
Lessee Leasing Arrangements, Operating Leases, Renewal Term	10 years
Lonza Group AG
Operating Leased Assets [Line Items]
Unrecorded Unconditional Purchase Obligation, Purchases		49,000
Lonza Group AG \| Construction in Progress [Member]
Operating Leased Assets [Line Items]
Construction-in-process asset		100,068	19,259
Lonza Group AG \| Facility Lease Obligation [Member]
Operating Leased Assets [Line Items]
Facility Lease Obligation, Noncurrent		$ 89,668	$ 15,229
Facility Lease Obligation, Payment Period		10 years
Inventories [Member] \| Lonza Group AG
Operating Leased Assets [Line Items]
Unrecorded Unconditional Purchase Obligation, Purchases		$ 42,630
Facility Lease Obligation [Member] \| Lonza Group AG
Operating Leased Assets [Line Items]
Unrecorded Unconditional Purchase Obligation, Purchases		$ 6,370

Commitments and Contingencies (Narrative) (Details) $ in Thousands	Sep. 30, 2016 USD ($)
Lonza Group AG
Other Commitments [Line Items]
Remaining total commitments	$ 1,122,029
Other Third Party Manufacturers
Other Commitments [Line Items]
Remaining total commitments	$ 33,000

Restructuring (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
Restructuring (Details) - USD ($) $ in Thousands	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Restructuring Cost and Reserve [Line Items]
Restructuring Charges	$ 564		$ 1,491
Relocation of European Headquarters
Restructuring Cost and Reserve [Line Items]
Restructuring Reserve, Period Increase (Decrease)	377	$ 4,312	2,392	$ 17,267
Employee Severance [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Charges	$ 0		$ 0
Synageva BioPharma Corp.
Restructuring Cost and Reserve [Line Items]
Restructuring Charges		$ 3,149		$ 13,470

Restructuring Restructuring Reserve Roll Forward (Details) - USD ($) $ in Thousands	3 Months Ended	9 Months Ended
	Sep. 30, 2016	Sep. 30, 2016	Jun. 30, 2016	Dec. 31, 2015
Restructuring Cost and Reserve [Line Items]
Restructuring Reserve	$ 2,162	$ 2,162	$ 2,428	$ 7,241
Restructuring Charges	564	1,491
Payments for Restructuring	(830)	(6,820)
Restructuring Reserve, Accrual Adjustment	0	250
Employee Severance [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Reserve	999	999	999	6,390
Restructuring Charges	0	0
Payments for Restructuring	0	(4,343)
Restructuring Reserve, Accrual Adjustment	0	(1,048)
Contract Termination [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Reserve	998	998	1,333	682
Restructuring Charges	0	35
Payments for Restructuring	(335)	(1,017)
Restructuring Reserve, Accrual Adjustment	0	1,298
Other Restructuring [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Reserve	165	165	$ 96	$ 169
Restructuring Charges	564	1,456
Payments for Restructuring	(495)	(1,460)
Restructuring Reserve, Accrual Adjustment	$ 0	$ 0

Fair Value Measurement (Schedule Of Assets And Liabilites Measured At Fair Value) (Details) - USD ($) $ in Thousands	Sep. 30, 2016	Dec. 31, 2015
Acquisition Related Contingent Consideration [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Business Combination, Contingent Consideration, Liability	$ 207,904
Cash Equivalents [Member] \| Money Market Funds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	83,864	$ 179,898
Cash Equivalents [Member] \| Money Market Funds [Member] \| Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	0	0
Cash Equivalents [Member] \| Money Market Funds [Member] \| Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	83,864	179,898
Cash Equivalents [Member] \| Money Market Funds [Member] \| Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	0	0
Cash Equivalents [Member] \| Commercial Paper [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	96,765	192,418
Cash Equivalents [Member] \| Commercial Paper [Member] \| Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	0	0
Cash Equivalents [Member] \| Commercial Paper [Member] \| Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	96,765	192,418
Cash Equivalents [Member] \| Commercial Paper [Member] \| Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	0	0
Cash Equivalents [Member] \| Corporate Bond Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	6,003	12,250
Cash Equivalents [Member] \| Corporate Bond Securities [Member] \| Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	0	0
Cash Equivalents [Member] \| Corporate Bond Securities [Member] \| Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	6,003	12,250
Cash Equivalents [Member] \| Corporate Bond Securities [Member] \| Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	0	0
Cash Equivalents [Member] \| Municipal Bonds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	93,659	60,001
Cash Equivalents [Member] \| Municipal Bonds [Member] \| Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	0	0
Cash Equivalents [Member] \| Municipal Bonds [Member] \| Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	93,659	60,001
Cash Equivalents [Member] \| Municipal Bonds [Member] \| Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	0	0
Cash Equivalents [Member] \| Certificates of Deposit [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	1,750	27,000
Cash Equivalents [Member] \| Certificates of Deposit [Member] \| Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	0	0
Cash Equivalents [Member] \| Certificates of Deposit [Member] \| Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	1,750	27,000
Cash Equivalents [Member] \| Certificates of Deposit [Member] \| Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	0	0
Cash Equivalents [Member] \| Other Government Obligations [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	26,002	31,549
Cash Equivalents [Member] \| Other Government Obligations [Member] \| Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	0	0
Cash Equivalents [Member] \| Other Government Obligations [Member] \| Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	26,002	31,549
Cash Equivalents [Member] \| Other Government Obligations [Member] \| Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	0	0
Marketable Securities [Member] \| Mutual Funds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Marketable securities	13,421	8,817
Marketable Securities [Member] \| Mutual Funds [Member] \| Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Marketable securities	13,421	8,817
Marketable Securities [Member] \| Mutual Funds [Member] \| Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Marketable securities	0	0
Marketable Securities [Member] \| Mutual Funds [Member] \| Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Marketable securities	0	0
Marketable Securities [Member] \| Commercial Paper [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Marketable securities	141,327	61,978
Marketable Securities [Member] \| Commercial Paper [Member] \| Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Marketable securities	0	0
Marketable Securities [Member] \| Commercial Paper [Member] \| Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Marketable securities	141,327	61,978
Marketable Securities [Member] \| Commercial Paper [Member] \| Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Marketable securities	0	0
Marketable Securities [Member] \| Corporate Bond Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Marketable securities	181,801	120,499
Marketable Securities [Member] \| Corporate Bond Securities [Member] \| Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Marketable securities	0	0
Marketable Securities [Member] \| Corporate Bond Securities [Member] \| Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Marketable securities	181,801	120,499
Marketable Securities [Member] \| Corporate Bond Securities [Member] \| Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Marketable securities	0	0
Marketable Securities [Member] \| Municipal Bonds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Marketable securities	61,647	27,110
Marketable Securities [Member] \| Municipal Bonds [Member] \| Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Marketable securities	0	0
Marketable Securities [Member] \| Municipal Bonds [Member] \| Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Marketable securities	61,647	27,110
Marketable Securities [Member] \| Municipal Bonds [Member] \| Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Marketable securities	0	0
Marketable Securities [Member] \| Certificates of Deposit [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Marketable securities	13,001
Marketable Securities [Member] \| Certificates of Deposit [Member] \| Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Marketable securities	0
Marketable Securities [Member] \| Certificates of Deposit [Member] \| Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Marketable securities	13,001
Marketable Securities [Member] \| Certificates of Deposit [Member] \| Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Marketable securities	0
Marketable Securities [Member] \| Other Government Obligations [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Marketable securities	137,910	156,500
Marketable Securities [Member] \| Other Government Obligations [Member] \| Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Marketable securities	0	0
Marketable Securities [Member] \| Other Government Obligations [Member] \| Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Marketable securities	137,910	156,500
Marketable Securities [Member] \| Other Government Obligations [Member] \| Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Marketable securities	0	0
Marketable Securities [Member] \| Equity Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Marketable securities	1,775
Marketable Securities [Member] \| Equity Securities [Member] \| Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Marketable securities	1,775
Marketable Securities [Member] \| Equity Securities [Member] \| Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Marketable securities	0
Marketable Securities [Member] \| Equity Securities [Member] \| Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Marketable securities	0
Prepaid Expenses and Other Current Assets [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Interest Rate Derivative Assets, at Fair Value	229
Prepaid Expenses and Other Current Assets [Member] \| Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Interest Rate Derivative Assets, at Fair Value	0
Prepaid Expenses and Other Current Assets [Member] \| Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Interest Rate Derivative Assets, at Fair Value	229
Prepaid Expenses and Other Current Assets [Member] \| Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Interest Rate Derivative Assets, at Fair Value	0
Prepaid Expenses and Other Current Assets [Member] \| Foreign Exchange Forward [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Foreign exchange forward contracts, asset	50,320	91,745
Prepaid Expenses and Other Current Assets [Member] \| Foreign Exchange Forward [Member] \| Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Foreign exchange forward contracts, asset	0	0
Prepaid Expenses and Other Current Assets [Member] \| Foreign Exchange Forward [Member] \| Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Foreign exchange forward contracts, asset	50,320	91,745
Prepaid Expenses and Other Current Assets [Member] \| Foreign Exchange Forward [Member] \| Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Foreign exchange forward contracts, asset	0	0
Other Noncurrent Assets [Member] \| Foreign Exchange Forward [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Foreign exchange forward contracts, asset	31,122	66,309
Other Noncurrent Assets [Member] \| Foreign Exchange Forward [Member] \| Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Foreign exchange forward contracts, asset	0	0
Other Noncurrent Assets [Member] \| Foreign Exchange Forward [Member] \| Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Foreign exchange forward contracts, asset	31,122	66,309
Other Noncurrent Assets [Member] \| Foreign Exchange Forward [Member] \| Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Foreign exchange forward contracts, asset	0	0
Other Current Liabilities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Interest Rate Derivative Liabilities, at Fair Value	946
Other Current Liabilities [Member] \| Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Interest Rate Derivative Liabilities, at Fair Value	0
Other Current Liabilities [Member] \| Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Interest Rate Derivative Liabilities, at Fair Value	946
Other Current Liabilities [Member] \| Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Interest Rate Derivative Liabilities, at Fair Value	0
Other Current Liabilities [Member] \| Foreign Exchange Forward [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Foreign exchange forward contracts, liability	34,944	5,648
Other Current Liabilities [Member] \| Foreign Exchange Forward [Member] \| Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Foreign exchange forward contracts, liability	0	0
Other Current Liabilities [Member] \| Foreign Exchange Forward [Member] \| Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Foreign exchange forward contracts, liability	34,944	5,648
Other Current Liabilities [Member] \| Foreign Exchange Forward [Member] \| Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Foreign exchange forward contracts, liability	0	0
Other Current Liabilities [Member] \| Acquisition Related Contingent Consideration [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Business Combination, Contingent Consideration, Liability	81,848	55,804
Other Current Liabilities [Member] \| Acquisition Related Contingent Consideration [Member] \| Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Business Combination, Contingent Consideration, Liability	0	0
Other Current Liabilities [Member] \| Acquisition Related Contingent Consideration [Member] \| Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Business Combination, Contingent Consideration, Liability	0	0
Other Current Liabilities [Member] \| Acquisition Related Contingent Consideration [Member] \| Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Business Combination, Contingent Consideration, Liability	81,848	55,804
Other Noncurrent Liabilities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Interest Rate Derivative Liabilities, at Fair Value	797
Other Noncurrent Liabilities [Member] \| Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Interest Rate Derivative Liabilities, at Fair Value	0
Other Noncurrent Liabilities [Member] \| Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Interest Rate Derivative Liabilities, at Fair Value	797
Other Noncurrent Liabilities [Member] \| Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Interest Rate Derivative Liabilities, at Fair Value	0
Other Noncurrent Liabilities [Member] \| Foreign Exchange Forward [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Foreign exchange forward contracts, liability	38,392	4,773
Other Noncurrent Liabilities [Member] \| Foreign Exchange Forward [Member] \| Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Foreign exchange forward contracts, liability	0	0
Other Noncurrent Liabilities [Member] \| Foreign Exchange Forward [Member] \| Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Foreign exchange forward contracts, liability	38,392	4,773
Other Noncurrent Liabilities [Member] \| Foreign Exchange Forward [Member] \| Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Foreign exchange forward contracts, liability	0	0
Contingent Consideration [Member] \| Acquisition Related Contingent Consideration [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Business Combination, Contingent Consideration, Liability	126,056	121,424
Contingent Consideration [Member] \| Acquisition Related Contingent Consideration [Member] \| Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Business Combination, Contingent Consideration, Liability	0	0
Contingent Consideration [Member] \| Acquisition Related Contingent Consideration [Member] \| Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Business Combination, Contingent Consideration, Liability	0	0
Contingent Consideration [Member] \| Acquisition Related Contingent Consideration [Member] \| Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Business Combination, Contingent Consideration, Liability	$ 126,056	$ 121,424